Hypertension management in primary care: could less mean more? by Wel, M.C. van der
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/107624
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Hypertension 
management 
in 
primary 
care: 
could 
less 
mean 
more?

Hypertension management in primary care: 
could less mean more?
Mark C. van der Wel
Design and Layout: Sander van der Wel 
Printed by: GVO Drukkers & Vormgevers BV, Ede
ISBN: 978-90-6464-631-7
This thesis was made possible by grants of: 
Department of Primary and Community Care, Radboud University Nijmegen Medical Centre
SBOH, employer of GP trainees
Copyright; 
© M.C. van der Wel, Nijmegen, the Netherlands, 2012. 
All rights reserved. 
No part of this book may be reproduced or transmitted in any form or by any means, 
without prior written permission of the holder of the copyright.
Hypertension management in primary care: 
could less mean more?
proefschrift
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof.mr. S.C.J.J. Kortmann,
volgens besluit van het college van decanen
in het openbaar te verdedigen op vrijdag 22 februari 2013 
om 13.00 uur precies
door
Mark Christian van der Wel
geboren op 1 augustus 1974
te Nieuw-Lekkerland
Promotoren:
Prof. dr. C. van Weel
Prof. dr. J.W.M. Lenders
Copromotoren:
Dr. J.C. Bakx
Dr. J. Deinum
Manuscriptcommissie:
Prof. dr. M.J. De Boer
Prof. dr. W.J.J. Assendelft
Dr. N.P. Riksen
Paranimfen:
Dr. T.C. olde Hartman
Drs. G.B.J.M. Keijzers
Panta rhei
Heraclitus, ca. 540-480 v. Chr.

Contents
Chapter 1                9
General Introduction
Huisarts Wet 2010;53(7): 392-98
Chapter 2              23
The influence of guideline revisions on the process and outcome of 
hypertension management in general practice: A descriptive study
Eur J GP. 2008; 14(Suppl 1): 7-52
Chapter 3              35
Thirty-minute compared to standardised office blood pressure measurement 
in general practice
Br J Gen Pract 2011; 61(590): e590-7 
Chapter 4              53
A Novel Approach to Office Blood Pressure Measurement: 30-Minute Office 
Blood Pressure vs Daytime Ambulatory Blood Pressure
Ann Fam Med 2011;9:128-135
Chapter 5              71
Comparison between supine, 30 minute, serial, automated office blood 
pressure and ABPM 
Submitted 
Chapter 6              87
Patient characteristics do not predict the individual response to 
antihypertensive medication: a cross-over trial
Submitted
Chapter 7            105
General Discussion
Epilogue            117
The art of parsimony in delivering care
Submitted
Summary             125
Samenvatting            129
Dankwoord            135
List of publications           141
About the author           145

Chapter 1 
General Introduction
Partly based on:  
Van der Wel MC, Deinum J, Bakx JC. 
Bloeddruk meten buiten de spreekkamer: de kloof tussen praktijk en wetenschap. 
Huisarts Wet 2010;53(7): 392-98
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chapter one
Relevance of research in hypertension
This thesis is yet another on the topic of hypertension. With 65,200,000 hits in Google and 
343,883 in Pubmed (22nd of April 2012) it has been an intensely studied subject for decades. 
One can wonder: are more citations really needed? In many of these citations the introductory 
words vary on the following theme: 
“Hypertension is the most relevant risk factor for cardiovascular disease. Its worldwide prevalence 
is reported to be 20-26%. 1Diagnosis is relatively straightforward and treatment options are 
multiple, cheap and widely available.2;3 Treatment is worthwhile, each 10 mmHg reduction in 
systolic blood pressure results in 21% reduction of coronary heart disease and 37% reduction 
of stroke.4;5 However, despite this knowledge the rates of diagnoses (50-70%) and control (30-
50%) have remained suboptimal over the last decades.6;7” 
 
While often these citations addressed the dismal control of hypertension, this constant repetition 
seems to have numbed the minds of doctors. Although some population studies demonstrate 
that control rates do improve 6;8, this improvement is still modest and we should not accept that 
results are not better than they are. 
The question then rises: how to improve hypertension control? 
One option could be to intensify screening in order to find all those patients with unrecognised 
hypertension. Additional options are the use of stricter targets, the development of new, more 
effective drugs, improvement of practice performance indicators and the creation of incentives 
to follow guidelines. 
Paradoxically, the research as described in this thesis is not about “more” but about “less” 
and is an attempt to reduce false positive labelling of hypertension and to contribute to the 
exploration of a more efficient use of the available medication by personalised antihypertensive 
medicine.
Hypertension management in primary care
Optimal control of hypertension starts with a correct determination of the blood pressure status 
of a patient and a subsequent correct diagnosis of hypertension. The correctly determined blood 
pressure should then be interpreted in the context of the total cardiovascular risk profile. This 
will result in a conclusion about the type of hypertension (primary or secondary), on whether or 
not to start medical treatment and if so, with what class of antihypertensive medication. 
These steps are described in depth in guidelines on hypertension management which serve as 
support for clinicians and as the professional standard of care.2;3;9 It is assumed that a guideline 
and its revisions (update with most recent scientific knowledge) will improve hypertension 
control. Adherence to guidelines by physicians is needed to actually achieve this improvement. 
The rather modest improvement of hypertension control rates over the last decades suggests 
that suboptimal physician adherence may be one of the factors to explain mediocre control of 
hypertension. 
11
general introduction
We wanted to enhance our understanding of hypertension management in primary care by 
exploring how the process and outcome of hypertension management was influenced by the 
Dutch guideline on hypertension management and its revisions. 
Diagnosis
The apparent simplicity of a blood pressure measurement is deceptive; compared to other 
cardiovascular risk factors, assessment of blood pressure is probably the most complicated. 
Factors impeding correct determination of blood pressure
Until now, office blood pressure measurement (OBPM) has been the cornerstone for diagnosis 
and management of hypertension.2;3;9 Unfortunately, OBPM is prone to different types of error, 
which in daily practice often will lead to an overestimation of the true blood pressure level. 
Therefore, guidelines include extensive protocols on how to measure blood pressure in a 
standardized way to eliminate most types of measurement error. This error can occur on the level 
of the observer, the patient, the measurement device and the environment of measurement.10;11 
Several studies have shown that blood pressure as measured by usual practice overestimates 
true systolic blood pressure by 10-14 mmHg as compared to blood pressure measured strictly 
according to guidelines.12;13 
Blood pressure is subject to substantial biological variability both short term (minutes-hours) 
and long term (weeks-months).14-17 This variability introduces noise in the assessment of the 
usual or “true” blood pressure of a patient and requires determination of a mean blood pressure 
based on multiple measurements over a prolonged period of time. It is this mean blood pressure 
that is considered to be the most important predictor of cardiovascular disease.2;3;9
Box 1: Definitions 3;25
White coat effect:
Condition of increased blood pressure measured by clinical staff in a clinical setting 
compared to blood pressure measured at home or during daily life. It is attributed to an 
alerting reaction, anxiety and/or conditioned response 
White coat hypertension:
Condition when office blood pressure is persistently elevated (≥ 140/90 mmHg) while 
daytime, 24-hour or home blood pressure is within the normal range
Masked hypertension: 
The reverse phenomenon of white coat hypertension, patients with normal 
(< 140/90 mmHg) office blood pressure but with elevated ambulatory or home blood 
pressure (≥ 135/85 mmHg)
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Besides measurement error the phenomenon of “white coat effect” (Box 1) also results in 
overestimation of true blood pressure. Unfortunately, this effect cannot be overcome with a fully 
standardized auscultatory blood pressure measurement. The prevalence of white coat effect is 
reported to be around 25%, depending on the studied population.18;19 Although some individual 
studies have shown that prognosis of patients with white coat effect is slightly worse compared 
to normotensive patients 20;21, data from a recent meta-analysis suggest that prognosis is the 
same.22 The introduction of automated, oscillometric blood pressure measurement devices 
enabled two seemingly straightforward methods of diagnosing the white coat effect: 24- 
hour ambulatory blood pressure measurement (24-hour ABPM) and home blood pressure 
measurement (HBPM).3;10;23;24  
In HBPM patients ideally take two consecutive measurements both in the morning and the 
evening for seven days in a row of which the mean of the last six days is used as outcome.3;23 
With 24-hour ABPM, blood pressure is measured each 15-20 minutes in the daytime and each 
30-60 minutes at night and results in several variables of which mean daytime, 24-hour and 
night time seem to be the most important.3;24 
These methods, however come with some disadvantages. 24-hour ABPM is costly, not suitable 
for all patients and because sleep is often disturbed many patients do not like to have 24-
hour ABPM more than once.26 HBPM is prone to measurement error, patients need to be able 
to understand and execute the measurement protocol and some patients may cheat with 
measurements or measurement results.27;28
Conception of the idea to validate serial automated OBPM (AOBPM)
Ideally, a simple method in the office would be able to overcome measurement bias and 
detect the white coat effect, thus avoiding overdiagnosis and overtreatment. In addition this 
measurement should be standardised, easy to execute correctly by all types of health care staff, 
patient friendly and straightforward to implement in daily practice.
We were inspired by outpatient hypertension clinics that used a blood pressure measurement 
lasting 30 minutes in supine patients alone in a quiet and comfortable room to estimate “basal” 
or “true” blood pressure. A purpose built measurement device was used for these serial, 
automated blood pressure measurements. Because of its costs wide scale use of this device 
in general practice seemed unlikely. In addition, proper validation of this measurement method 
was lacking. We therefore decided to validate a 30-minute AOBPM using a 24-hour ABPM 
device. These devices have become routine equipment for most Dutch general practices or are 
readily available in most primary care diagnostic centres. 
 
Study of the literature at the time of conception of our idea revealed that data on AOBPM were 
exceptionally scarce. Some research had shown the use of ABPM in shorter time periods from 
12 to 4 hours, but not shorter.29-31 One research group had just started to study AOBPM with the 
use of a purpose built device (BPTru) able to measure blood pressure five times consecutively 
at one or two minute intervals.32;33 This device was also expensive and the short measurement 
time conflicts with data suggesting that blood pressure in serial measurements reaches a 
steady state not before 10 minutes.34
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Treatment
Personalized medicine
Once a patient is correctly diagnosed with essential hypertension and the indication for medical 
treatment is set, lack of adherence to relevant guidelines by physicians and lack of adherence to 
prescribed treatment by patients are the two most important causes of suboptimal hypertension 
control.8;35
Personalised medicine is suggested to be one of several approaches that could improve treatment 
adherence of patients and as such might be useful in hypertension management. In this thesis 
we define personalised medicine as an approach where individual patient characteristics are 
used to identify the best possible treatment for that particular patient. This approach assumes 
that one or more patient characteristics have the ability to predict the response to treatment and 
enable selection of the drug of first choice for a given patient. This selected drug should have 
the best efficacy with the lowest risk of adverse events. As a consequence patients will be more 
motivated to continue treatment.36 This should then result in a reduction of the number of drugs 
needed to reach treatment goals. 
Data from several studies suggest that patient tailored treatment is indeed possible in hypertension 
management. In primary care, physicians choose from four different classes of antihypertensive 
drugs to start treatment: angiotensin converting enzyme inhibitors (ACEi), angiotension receptor 
blockers (ARB), β blockers, calcium channel blockers (CCB) and/or diuretics. Although meta-
analyses have concluded that these different classes of antihypertensive medication are on 
average equally efficacious in blood pressure reduction,37;38 several other studies have shown 
that at the patient level large intra-individual differences in blood pressure response to these 
different classes exist.39-41 
The most widespread explanation for these intra-individual differences in response comes 
from a simplified pathophysiological model of essential hypertension in which patients can 
be positioned on a scale ranging from high renin, vasoconstriction-driven hypertension to low 
renin, salt-sensitive/volume-driven hypertension.42 This model was formulated only some years 
after the discovery of renin-angiotensin-aldosterone-system (RAAS) around 1960.43;44
In combination with knowledge on the working mechanism of the different classes of 
antihypertensive drugs in theory this model could be the key to successful personalised 
hypertension management in patients with essential hypertension. After all, ACEi, ARB and 
beta-blockers suppress the RAAS and therefore might work best in high renin hypertension. 
In contrast, diuretics and CCB reduce sodium and volume and might work better in volume 
driven (low renin) hypertension. Based on this theory plasma renin, but – as proven or assumed 
surrogates for renin status – also age, ethnicity, BMI and waist circumference have been studied 
as potential predictive variables (table 1).
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Besides this renin based model, alternative concepts are less well described and have a 
limited evidence base. Both the role of sex, through hormonal influences on blood pressure 
regulation 45 and NT-proBNP, in relation to obesity driven down regulation 46;47, in theory could 
have predictive potential. 
Previous research on predictors and its limitations
The search for predictors has been limited to a relatively small number of studies which have 
had conflicting results as can be seen in Table 1. Only the role of ethnicity as predictor of 
treatment response has been acknowledged by all international guidelines.2;3;9;48
Many of the studies addressing personalised hypertension management came with serious 
methodological and practical limitations. First of all the correct measurement of renin has long 
been subject of debate. Although current assays of plasma renin activity and plasma renin 
concentration are now reliable, previous assays had low inter-laboratory reproducibility 69-71 
which is likely to have contributed to the inconclusive results of previous studies. In addition, 
laborious demands of previous plasma renin activity assays, particularly if sodium profiling was 
required, were never successfully implemented in routine primary care. Second, in most studies 
women were heavily underrepresented. Third, quite a number of studies seemed to be rather 
underpowered 50;54;59;63-65 to draw firm conclusions. Fourth, only a small number of studies was 
primarily aimed at identifying predictors of treatment response. Finally, many studies presented 
data of diastolic blood pressure as opposed to current guidelines that advocate management 
based on systolic blood pressure.
Moreover only a very limited number of studies involved patients included in primary care. 
The patient selection from often specialised hypertension clinics may have introduced bias 
which limits generalisability to the general practice population.72 Selection of patients in these 
specialised clinics is prone to include more complicated types of hypertension. The relative 
low mean age of patients in many of these studies points in that direction. This age was 
often considerably lower than the mean age of diagnosis of hypertension in general practice 
populations, which lies around 55-60 years.73;74
Therefore we developed a study with the primary objective to identify predictors of the 
antihypertensive response to two classes of antihypertensive drugs with different mechanisms 
of action (ARB and diuretic) in a representative sample of the general practice population and 
with a set of potential predictors that are feasible to implement in the general practice setting.
Objectives of this thesis
Our first objective was to improve the understanding of the process and outcome of hypertension 
management in relation to the publication of the guidelines on hypertension of the Dutch 
College of General Practitioners. Our research question was:
What is the impact of guideline revisions on the process and outcome of hypertension 
management in primary care?  (Chapter 2)
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Second, we aimed to improve the diagnosis of hypertension by validating the concept of 
an AOBPM in a primary care population using an ABPM device. Such type of measurement 
would be much quicker than ABPM and HBPM, easier and more patient-friendly in repeat 
measurements and suitable for patients not willing or able to use ABPM or HBPM. Our research 
questions were:
Is there agreement between the sitting 30-minute AOBPM and standardized OBPM? 
(Chapter 3)
What is the reproducibility of the sitting 30-minute AOBPM? (Chapter 3)
Is there agreement between the sitting 30-minute AOBPM and daytime ABPM? 
(Chapter 4)
Is there agreement between the supine 30-minute AOBPM and daytime ABPM? 
(Chapter 5)
Third, we questioned whether we could identify patient characteristics that predict blood 
pressure response to two classes of antihypertensive drugs, each interfering with a different 
pathophysiological pathway of hypertension. We purposely selected patient characteristics that 
have been validated, are reproducible and can easily be used in primary care. Results of this 
study may help to improve hypertension treatment and control. Our research question was:
Are there patient characteristics that can predict the response to either       
hydrochlorothiazide (diuretic) or valsartan (ARB) in the treatment of newly diagnosed 
hypertensive patients in primary care? (Chapter 6)
Finally, we have put the results of our findings in the perspective of changes in society and the 
medical profession. Our research tried to contribute to reduction of false positive diagnoses 
and overtreatment of hypertension. However, we have noticed that medico-legal changes, pay 
for performance, societal perception on health, autonomy and risk seems to put pressure on 
doctors to overdiagnose and treat rather than vice versa. In our essay we propose a change for 
the better. (Epilogue)
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Table 1. Overview of available evidence for and against potential predictors of treatment 
response to the four major classes of antihypertensive medication
All numbers refer to references; 
BMI = body mass index; 
ACEi = angiotensin converting enzyme inhibitor; 
CCB = calcium channel blocker
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Abstract
Background: Blood pressure does not reach guideline targets in the majority of hypertensive 
patients. Longitudinal data from general practice records on trends in hypertension management 
and the influence of guideline changes are lacking. 
Objective: To describe the longitudinal impact of guideline revisions on the process and 
outcome of hypertension management in a primary care based database. 
Methods: We extracted data from the Nijmegen Monitoring Project (NMP), an academic 
practice-based research network with 50.000 patients listed. Based on the years of publication 
of the first Dutch guideline on hypertension (1991) and two revisions (1997 and 2003), we 
formed three cohorts of patients newly diagnosed with hypertension. We compared data such 
as patient characteristics, 2-year blood pressure course, type of first-choice antihypertensive 
drugs, and number of medications after 2 years of treatment. 
Results: Both the mean age at time of diagnosis of hypertension and pulse pressure rose 
between cohorts. In agreement with revisions in the guidelines, the use of diuretics as first-
choice drugs increased significantly from the first to the last cohort. The percentage of patients 
with three or more antihypertensive drugs remained equal. The relative 2-year systolic blood 
pressure decline did not differ with clinical relevance between the cohorts.
Conclusion: Our study has demonstrated that general practitioners achieve substantial and 
prolonged blood pressure reduction. However, guideline revisions do not seem to influence 
the amount of reduction, despite clear formulation of stricter treatment goals. In addition to 
qualitative research to identify the causes of this phenomenon, research to evaluate the effect 
of expert support systems on risk awareness and risk gain by additional treatment is necessary.
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Introduction
International guidelines on hypertension and cardiovascular risk management stress the 
importance of strict blood pressure regulation, defining targets that have become increasingly 
demanding over the last few decades.1-5 Despite these guidelines, blood pressure decrease - often 
expressed as control rates - appears to be insufficient. In addition, these rates have improved little 
in recent decades.6 Control rates can easily be misinterpreted or misused, because they depend 
highly on the population and hypertension guideline under study.7,8 Therefore, research data 
on quality of care solely based on control rates need to be scrutinized with caution. The current 
approach to hypertension in the context of cardiovascular risk management demonstrates a 
lack of cost effectiveness in ‘‘controlling’’ all hypertensive (≥ 140/90 mmHg) patients in primary 
care or the open population.3,4 Of course, hypertension management in general practice 
could be improved. Both patient-related factors (e.g., comorbidity, poor treatment adherence) 
and doctor-related factors (e.g., lack of knowledge of guideline content, disagreement with 
guidelines) contribute to substandard treatment of population-based blood pressure7. However, 
it is hard to accept that all the efforts of both researchers and guideline developers to improve 
blood pressure outcomes seem to have been of little value. We hypothesized that interpretation 
of the progress (or lack thereof) of blood pressure management over the last few decades is 
biased by comparing data of different populations in different settings using different types of 
guidelines (or using current guideline definitions retrospectively). Therefore, we studied the 
impact of guideline revisions on the process and outcome of hypertension management in one 
primary care based database that has continuously and structurally monitored hypertension 
management since 1986: the Nijmegen Monitoring Project, the Netherlands. 
Methods
Database
We extracted data from the Nijmegen Monitoring Project (NMP), a research database involving 
nine practices. The practices were fully computerized and had approximately 50.000 patients 
listed in total, with a sex and age distribution representative for the general Dutch population. 
The historical background of the NMP has been described in further detail in the editorial of this 
issue. The database was founded in 1986 to monitor the management of three common chronic 
conditions: hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. A 
specific data extraction form was filled in for each condition-related consultation. In the case 
of hypertension, several aspects were recorded: the diagnostic process; cardiovascular risk 
factors; type of treatment (with or without medication); initiation of drug treatment; type of 
medication; changes in medication or dosage; and control/evaluation moments. The quality of 
the data was ascertained by monthly meetings of representatives of all nine practices on quality 
control, knowledge, and protocol development, and annual feedback on process and outcome. 
Blood pressure management 
Practice protocols for blood pressure measurement and management (including diagnosis) of 
hypertension are based on the guidelines of the Dutch College of General Practitioners (most 
recent guideline: ‘‘Cardiovascular Risk Management’’, 2006). 9 Over the last few decades, 
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protocols have been adjusted when guideline updates contained relevant changes. Since 
the start of the NMP, the first hypertension guideline and two guideline updates have been 
published.1-3
Population and data collection
Based on the year of publication of the original 1991 and revised (1997 and 2003) hypertension 
guidelines, we formed three cohorts of patients newly diagnosed with hypertension. Patients 
for cohort 1 were selected in the period 1992-1996; for cohort 2 in the period 1998-2002; 
and for cohort 3 in the period 2004-2006. Not all hypertensive patients of the NMP practices 
were included in the study cohorts. Only patients treated with medication, with follow-up data 
covering a minimum of 2 years, and at least one blood pressure related consultation per 
year were included. In Table 1, we have summarized the key points of the guidelines used in 
this study according to four domains. Based on these domains, we have formulated several 
hypotheses about the expected change in actual diagnosis and management of hypertension 
in daily practice during the periods under study. For domain 1, we hypothesized an increase 
in the prevalence of hypertension and a decrease in the mean age of the cohorts. For domain 
2, we expected an increase in the number of people treated with medication (increase in 
cohort size) and no change in the mean blood pressure at time of diagnosis. For domain 3, 
we expected an increase in the achieved systolic blood pressure reduction. For domain 4, we 
hypothesized an increase in the use of diuretics and beta-blockers as first-choice drugs; in 
addition, we hypothesized an increase in the percentage of patients on two or more types of 
antihypertensive drugs.
Analysis
Descriptive statistics were used where applicable. We used Mantel-Haenszel chi-square tests 
to determine significance in trends for variables expressed in percentages. Analysis of variance 
(ANOVA) testing was used to compare cohorts for differences in continuous variables such as 
age and blood pressure. All statistical analyses were performed with SAS software, version 9.1.
Results
In the studied period of 1992-2006, 2251 patients were registered with newly diagnosed 
hypertension by general practitioners (GPs) working in the NMP practices. Of these patients, 
2021 (90%) started on medication at the time of diagnosis or the first blood pressure control 
thereafter. The mean blood pressure was 176/102 mmHg compared to 165/99 mmHg in the 
10% of patients without medication. Two or more years of follow-up data were lacking for 945 
patients. In 56% of these patients, the diagnosis of hypertension was made in the last 2 years of 
cohort period 3, so that it was not possible to obtain 2 years of follow-up data; in 30% of patients, 
control frequency was irregular and therefore did not meet the inclusion criteria. Other reasons 
were: patient died (4.1%), patient moved (4.8%), and miscellaneous (5.2%). An overview of 
the patient characteristics for each of the three studied cohorts is given in Table 2. The mean 
age rose significantly (p <0.0001); the mean diastolic blood pressure at time of diagnosis 
decreased significantly (p <0.0001). The age-adjusted prevalence of registered hypertension 
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in the NMP practices increased in the last decade, from 5.5% in 1995 and 6.1% in 2000 to 7.0% 
in 2005. Table 3 depicts the 2-year course of blood pressure for all three cohorts. In addition to 
the absolute decline, the table denotes the relative decline, correcting for the influence of an 
initial higher blood pressure on the potential of blood pressure decrease. The relative 2-year 
decline in systolic blood pressure was significantly lower in the first cohort compared to the 
other two cohorts. In contrast, the diastolic blood pressure decline was significantly lower in the 
last cohort as opposed to the other two. The effect of guidelines on the prescription of types 
of antihypertensive medication at initiation of treatment can be derived from Table 4. While 
in cohort 1, beta-blockers were the first choice of treatment, in cohort 3 this had changed in 
favour of diuretics. In all three cohorts, approximately one-third of all patients were using one 
hypertensive medication after 2 years of treatment (Table 5), and the number of patients on 
three or more medications was constant (p = 0.743). 
Discussion
Summary of main results
Patients in cohort 3 were significantly older and had a significant higher pulse pressure than 
patients in cohort 1. In accordance with guideline revisions, diuretics became the first-choice 
drugs. Despite stricter and more clearly formulated treatment goals, the percentage of patients 
on three or more medications remained constant in all three cohorts. No clinically relevant 
changes were noted in blood pressure outcome, with 2-year systolic blood pressure reduction 
ranging from 13.3 to 15.7% (24 to 29 mmHg) between cohorts.
Interpretation of results
To our knowledge, no previous study has longitudinally evaluated hypertension management in 
general practice based on 15 years of data from the same general practice research network. 
The changed perspective from focus on diastolic (1991 guideline) to systolic blood pressure in 
the context of 10-year absolute cardiovascular risk (2003 guideline) may explain the significant 
rise in mean age from cohort 1 to cohort 3.1,3 In hindsight, applying current knowledge and 
guidelines of cardiovascular risk management, it could be that part of the (younger) population 
of cohort 1 was overtreated. The rise in the age-adjusted prevalence of hypertension in our 
study has also been demonstrated in population-based surveys.10,11 Part of this rise may be 
explained by the lower cut-off levels used to define hypertension over the last 15 years. In theory, 
every lower cut-off level to define hypertension should result in a substantial rise in prevalence. 
However, general practitioners will often not register a patient to be hypertensive before he 
or she wants to initiate medical treatment. Therefore, our reported prevalence is substantially 
lower than those derived from the open population by screening and does not rise steeply.10,11 
Stricter hypertension definitions do not automatically imply that treatment is initiated sooner. 
With the introduction in recent years of cardiovascular risk functions, the use of cardiovascular 
risk factors other than hypertension in the assessment whether antihypertensive medication is 
indicated has become more refined. However, in essence, this approach was already applied 
in the 1991 guideline (see Table I). The outcome of blood pressure management, expressed in 
terms of relative 2-year systolic blood pressure reduction, did not differ substantially between 
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cohorts. We would like to highlight two possible interpretations of this result. First, although 
changes in cut-off levels to define hypertension have caused more patients to be labelled as 
hypertensive, indications for medical treatment have only changed moderately throughout the 
years, and, for younger patients in particular, seem to even have become less strict. Second, 
treatment goals have been defined more clearly and have become stricter in the course of 
guideline revisions. Therefore, although medical treatment should in subgroups of patients 
be initiated at a later stage than in previous years, if treatment is indicated, it should reach 
stricter targets. In this respect, the unchanged blood pressure reduction as reported in our 
study is disappointing. Our results, as shown in Table 5, are in agreement with previous studies 
and show that somehow doctors are reluctant to prescribe three or more antihypertensive 
medications, even when treatment goals are not reached.12,13 However, it is important to stress 
that the reported blood pressure reduction that was achieved in all three cohorts matches or 
exceeds that of results in the severely controlled environment of selected patients in randomized 
controlled trials (RCTs). 14-16
Limitations
It is essential for optimal interpretation of our presented results to realize that data were derived 
from a well-described part of the hypertensive population of the NMP practices. We have 
not described patients registered with hypertension but not using medication, or the group 
of patients known to have high blood pressure but not yet registered by their GP as being 
hypertensive. The NMP practices form an academic research network. The mere fact that these 
practices monitor chronic diseases will have enhanced the quality of care. As a consequence, 
our results may not fully represent average general practice in the Netherlands and may 
overestimate the quality of the process and outcome of hypertension management. The last 
study cohort was relatively small compared to cohorts 1 and 2. In addition, compared to the 
first two cohorts, the number of patients in cohort 3 for whom the new guideline could be best 
applied were lacking. We assume it takes 1-2 years after the introduction of a new guideline 
before any kind of homeostasis is reached with regard to the application of new guideline 
recommendations in daily practice. In this respect, the results of cohort 3 could change for the 
better with two additional follow-up years (equal to cohorts 1 and 2).
Conclusion
Our study demonstrates the relevance of longitudinal data recording in understanding the 
management of chronic conditions. This type of data recording in one research network forms 
the basis of truly comprehending and interpreting medical outcomes in the context of the 
inevitable revisions in guidelines and protocols. Guidelines and guideline revisions do result in 
changes in the process of hypertension management, but the resultant blood pressure outcome 
has not changed with any clinical relevance over the last 15 years. General practitioners achieve 
substantial and prolonged blood pressure reduction, which equals or exceeds reductions 
achieved in RCTs. However, despite the clear formulation of stricter treatment goals in the 
revised guidelines, general practitioners appear to be reluctant to subscribe three or more 
antihypertensive medications. In addition to qualitative research to identify the causes of this 
29
proces and outcome of hypertension management
phenomenon, research to evaluate the effect of expert support systems on risk awareness and 
risk gain by additional treatment is necessary. 
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Table 1. Summary points of hypertension guidelines in studied period  
DBP = diastolic blood pressure; 
SBP = systolic blood pressure; 
CVD = cardiovascular disease; 
DM = diabetes mellitus; 
ACE = angiotensin converting enzyme 
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Table 2. Characteristics of study population (at time of diagnosis hypertension)  
Table 3. Two-year course of blood pressure per cohort   
BMI = body mass index; 
SBP = systolic blood pressure; 
DBP = diastolic blood pressure; 
† p < 0.0001 for difference between cohorts
SBP = systolic blood pressure; 
DBP = diastolic blood pressure; 
‡ p = 0.002 compared to cohort 2, p = 0.190 compared to cohort 3; 
† p = 0.02 compared to cohort 1, p = 0.027 compared to cohort 2 
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Table 4. Type of initial drug choice in patients who have started on mono therapy 
Table 5. Mono-duo-triple therapy per cohort at time of diagnosis and after two years of treatment 
(in % of patients)  
ACE = angiotensin converting enzyme; 
ARB = angiotensin receptor blocker; 
CCB = calcium channel blocker; 
† p = 0.121 for difference between cohorts; 
‡ p = 0.001 for difference between cohorts
tdiag = time of diagnosis
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Abstract
Background: Although blood pressure measurement is one of the most frequently performed 
measurements in clinical practice, there are concerns about its reliability. Serial, automated 
oscillometric blood pressure measurement has the potential to reduce measurement bias and 
‘white coat effect’.
Objective: To study agreement of 30-minute office blood pressure measurement (OBPM) with 
standardised OBPM, and to compare repeatability.
Methods: In a method comparison study executed in two general practices, 30-minute and 
standardised OBPM was carried out with the same, validated device in 83 adult patients. 
The procedure was repeated after 2 weeks. During 30-minute OBPM, blood pressure was 
measured automatically every 3minutes, with the patient in a sitting position, alone in a quiet 
room. Agreement between 30-minute and standardised OBPM was assessed by Bland–
Altman analysis. Repeatability of the blood pressure measurement methods after 2 weeks was 
expressed as the mean difference in combination with the standard deviation of difference 
(SDD).
Results: Mean 30-minute OBPM readings were 7.6/2.5mmHg (95%confidence interval [CI] = 
6.1 to 9.1/1.5 to 3.4mmHg) lower than standardized OBPM readings. The mean difference and 
SDD between repeated 30-minute OBPMs (mean difference = 3/1mmHg, 95%CI = 1 to 5/0 to
2mmHg; SDD 9.5/5.3mmHg) were lower than those of standardised OBPMs (mean difference 
= 6/2mmHg, 95%CI = 4 to 8/1 to 4mmHg; SDD 10.9/6.3mmHg).
Conclusion: Thirty-minute OBPM resulted in lower readings than standardised OBPM and had 
a better repeatability. These results suggest that 30-minute OBPM better reflects the patient’s 
true blood pressure than standardised OBPM does.
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Introduction
In everyday practice, blood pressure measurements are often of poor quality, mostly resulting 
in overestimation of the patient’s blood pressure.1 But, even when performed according to 
the ‘state of the art’, blood pressure measurements in the office may not be representative 
of the patient’s true blood pressure status because the phenomenon ‘white-coat effect’ can 
introduce an additional level of bias.2 Overestimation of blood pressure leads to overprescribing 
of antihypertensive drugs, with avoidable side effects and costs. Until recently, observer bias 
and ‘white-coat effect’ could be eliminated sufficiently only with the ambulatory blood pressure 
measurement techniques like home blood pressure monitoring and ambulatory blood pressure 
monitoring (ABPM).3,4 However, these advantages of ambulatory techniques come with a price. 
ABPM is not very patient friendly,5 and is associated with disturbed sleep.6 Home blood pressure 
measurements may be inaccurate because of poor measurement technique7 and report bias.8 
These aspects make ABPM techniques less suitable for routine use in daily practice.
Serial automated blood pressure measurement, without a doctor or nurse present, also 
has the potential to eliminate observer bias and reduce ‘white-coat effect’.9–12 Compared to 
ambulatory techniques, this could be used much more easily in routine practice. The results are 
available during a single consultation, and the procedure appears to be more patient friendly 
than ABPM. In a recent study, 30-minute automated blood pressure measurement (30 minute 
OBPM) agreed well with daytime ABPM and classified normotension, ‘white-coat hypertension’, 
masked hypertension, and sustained hypertension similarly to daytime ABPM.13 The aim of this 
study was to compare 30-minute OBPM with standardised OBPM in general practice. The level 
of agreement between both methods was studied and the repeatability compared.
Method
Design
A method-comparison study was performed to investigate how 30-minute OBPM agreed with 
standardised OBPM. As part of the method comparison, a repeatability study of 30-minute 
OBPM compared to standardised OBPM was carried out.14
Participants and setting 
The study took place in two general practices of the academic practice-based research network15 
of the Radboud University Nijmegen Medical Centre. Each consecutive patient who attended 
the practice with a main reason for encounter that warranted blood pressure measurement 
was invited by the practice assistant to participate in the study. Patients gave written informed 
consent before participation. Exclusion criteria were atrial fibrillation, documented heart valve 
disease, complete axillary lymph node excision on the right side, and upper arm circumference 
more than 35 cm. Smoking, diabetes, cardiovascular disease, and medication were recorded. 
Blood pressure measurements 
Both standardised OBPM and 30-minute OBPM were taken with the same, validated, automated 
oscillometric device, the Mobil- O-Graph NG (IEM GMBH, Stolberg, Germany).16 The devices are 
calibrated annually. Different bladder sizes were used to match the different arm circumferences. 
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Two researchers were trained to perform the OBPMs according to a detailed protocol (available 
on request) based on the recommendations of the European Society of Hypertension17 and the 
American Heart Association.18 The key elements of this protocol are listed in Boxes 1 and 2. 
During visit 1, standardised OBPM was carried out after a 5-minute rest period in the absence of 
the observer. The measurement consisted of three readings. Immediately afterwards, 30-minute 
OBPM followed, consisting of 11 measurements, of which 10 were made in the absence of 
the researcher. The position of the patient and cuff were not altered. The result of the first 
measurement of both standardised and 30-minute OBPM was discarded. After 2 weeks, the 
measurements were repeated by the same researcher in the same room at the same time of 
the day (visit 2). To assess whether the measurement order influenced the results, an additional 
standardised OBPM was performed after the second 30-minute OBPM. The last noted usual 
Box 1. Key elements of blood pressure measurement
Key elements of standardised office blood pressure measurement
• No talking
• Temperature in the room22 degrees Celsius
• Right arm
• Placement of the cuff: 2 cm above antecubital fossa
• Position of patient: sitting, back supported, feet flat on the floor, middle of cuff on 
level on right atrium
• 5 minutes’ rest in the absence of the observer before office blood pressure 
measurement
• 3 readings with 30 seconds in between, first reading discarded
Key elements of 30-minute automated office blood pressure measurement
• Same position of patient and cuff as in standardised office blood pressure 
measurement
• 30 seconds after standardised office blood pressure measurement, observer checks 
first
• measurement, then leaves the room. Patient stays in same position
• 11 measurements every 3 minutes, first measurement discarded
Box 2. Overview of study method
Time
Retrospectively   Usual blood pressure
Visit 1, T = 0  Standardised OBPM   30-minute OBPM
Visit 2, T = 2 weeks Standardised OBPM   30-minute OBPM   Standardised OBPM
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blood pressure measurement was collected, to compare with the study’s standardised 
procedure (Table 1). The last ‘usual blood pressure’ was not included if there had been a 
medication change between this measurement and the start of the study. 
Sample size 
A priori, a difference in blood pressure of 5mmHg or more was deemed to be clinically relevant. 
To detect such a difference with a power of 90%, a significance level of 5%, and assuming 
a standard deviation of the difference (SDD) of 14mmHg, 82 patients would be needed. 
Considering a drop-out of 20%, the study aimed to recruit 110 participants. 
Statistical methods
All data were registered and analysed in SPSS (version 16). Data were excluded for analysis 
if there was a change of medication type or doses between the two visits, or if fewer than 
nine measurements were valid during the 30-minute OBPM. The level of agreement between 
standardised OBPM and 30-minute OBPM was assessed by Bland and Altman’s approach 
of difference-against-mean plots.19 Because the difference increased with increasing blood 
pressure (positive rank correlation between the standard deviation [SD] and mean of the two 
blood pressure measurement methods), data were logarithmically transformed.14 The back-
transformed limits of agreement were added to Bland–Altman plots on the original scale.20 For 
comparison of means, 95% confidence intervals (CIs) were presented. For evaluation of the 
repeatability, the mean difference was used in combination with the SDD. The repeatability of the 
two methods was compared by performing the Wilcoxon signed-rank test on the difference of 
the SD of the (logarithmically transformed) standardised OBPMs and of the SD of the 30-minute 
OBPMs.
Results
Participants
A total of 105 patients agreed to participate in the study. Twenty-two patients were excluded 
from analysis, 10 because fewer than nine measurements of 30-minute OBPM were valid, six 
because of medication change between the two visits, two because they felt unwell during the 
measurements, two because they altered the position of their arm during the measurements, 
and two because they were unable to come for the second visit. The characteristics of included 
patients are shown in Table 1. 
Agreement between 30-minute OBPM and standardised OBPM 
Mean 30-minute OBPM readings were significantly lower than standardised OBPM readings, 
with a mean (absolute) difference of 7.6/2.5mmHg (Table 2). 
Figure 1a and 1b shows Bland–Altman plots of systolic and diastolic blood pressures during the 
first visit. These plots show the differences between 30-minute and standardized OBPM against 
their mean. As the difference increased with increasing blood pressure, the diverging limits of 
agreement were based on back transformation of results of logarithmically transformed data. 
The median difference in systolic blood pressure between standardised OBPM and 30-minute 
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OBPM was 6% (95% limits of agreement ranging from -4% to 15%). The median difference in 
diastolic blood pressure between standardised OBPM and 30-minute OBPM was 3% (95% 
limits of agreement from -7% to 13%).
Repeatability of standardised and 30-minute OBPM
Table 2 gives an overview of the data on visit 1 and 2 for both measurement methods. The mean 
difference between the first and second visit of 30-minute systolic OBPM is about half the mean 
difference of standardised OBPM. In addition, SDDs of repeat 30-minute OBPM were smaller 
than SDDs of repeat standardised OBPM. The Wilcoxon signed-rank test demonstrated that 
repeatability was significantly better for 30-minute OBPM than for standardized OBPM (P<0.01 
for systolic and diastolic blood pressure). 
Figures 2a and 2b presents Bland–Altman plots of the repeatability of systolic blood pressure 
for standardised and 30- minute OBPM respectively. The 95% limits of agreement are wider 
for standardized than for 30-minute systolic blood pressure (for data on the repeatability of 
diastolic blood pressure see Table 2; a figure is available on request). 
Measurement order 
Comparing blood pressures measured by standardised OBPM before (128.4/81.8mmHg) 
and after (128.3/82.1) the second 30-minute OBPM (visit 2) demonstrated that the order of 
measurement did not influence the results (difference (0.1/–0.3mmHg; 95 % CI = –1.6 to 1.9/–
1.2 to 0.6mmHg) [SDD 7.9/4.0 mmHg]).
Discussion
Summary
In this study, mean 30-minute OBPM readings were significantly lower than standardised 
OBPM readings, with a difference of 7.6/2.5mmHg. The repeatability in 2 weeks was better for 
30-minute OBPM than for standardised OBPM: the difference and the SDD in both systolic and 
diastolic blood pressure between the two visits were significantly lower for 30- minute than for 
standardised OBPM. 
Strengths and limitations 
This study has several strengths. It was carried out in a general practice setting, where most 
hypertension management takes place. It is the first study to perform serial automated OBPM 
(AOBPM) in general practice, with a common 24-hour ambulatory device. The advantage is that 
many practices already own one of these devices, and they are likely to be standard equipment 
in all general practices in the near future. With one type of device (and consequently just one 
type of software), practices can then run both office and ambulatory measurement protocols. 
The presentation of data on repeatability is of additive value in judging serial AOBPM in the 
office.
This study did not randomise the measurement order, which would have been methodologically 
more accurate. To study whether any time effect would bias the results, a second standardised 
OBPM was added after 30-minute OBPM. Standardised office blood pressure before and after 
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30-minute OBPM did not differ, so random measurements appear to have had no significant 
effect on the results. By introducing 30-minute OBPM, the study aimed to reduce the ‘white-
coat effect’ by leaving the patient alone in a room. The practice setting, which is also part of the 
‘white-coat effect’, may still contribute to a blood pressure rise. Thirty-minute OBPM takes less 
time from a healthcare professional than the 8–12 minutes required for a standardized OBPM.1 
However, it takes organizational skills and a spare room to implement 30-minute OBPM in daily 
practice. Previous research suggests that a duration of 30 minutes may not be necessary.13 
A shorter measurement time may help to overcome organisational problems. Results were 
presented both absolutely and relatively. The data in Table 2 were presented in absolute figures. 
However, it is important to realise that the presented results depend on the height of the blood 
pressure. Therefore, a relative measure is, strictly speaking, more appropriate. Most data were 
analysed in this relative form (after log transformation) as can be seen in the Bland–Altman 
plots, but to facilitate interpretation and enable comparison with other studies, absolute figures 
are presented in Table 2. 
Comparison with existing literature 
The study data support abundant evidence on the difference between usual blood pressure 
measurement and standardized OBPM based on measurement bias.1,21 In real life, the difference 
between office blood pressure measurement and 30-minute OBPM will be greater than the 
difference found in  this study, as lack of measurement technique in daily practice will lead to 
higher blood pressure results.
The mean last noted usual systolic blood pressure was 18mmHg higher than standardised 
OBPM (Tables 1 and 2). With the choice to compare 30-minute OBPM with standardised OBPM, 
measurement, bias was eliminated as potential (confounding) cause for a difference in blood 
pressure. It is therefore hypothesised that the presented difference in blood pressure is a result 
of the reduction of the ‘white-coat effect’ with 30-minute OBPM. The fact that standardised 
OBPMs before and after 30-minute OBPM were the same, underlines that a fall in blood 
pressure during 30-minute OBPM is influenced by the absence of the healthcare professional 
(and, less so, caused by a long rest period or regression to the mean). Other studies also 
demonstrated that repeated automated measurements with the patient alone in an examining 
room give lower results than standardized measurements. Recently, Myers et al found a 
difference of 5.4/2.1 mmHg between automated office blood pressure and conventional manual 
office blood pressure.22 These findings, which point in the same direction of lower results of 
automated measurements, are interesting, as their approach differed from the present one in 
two aspects: the researchers followed a shorter measurement procedure (10 minutes) and they 
used routine — not standardised — OBPM as the reference. It would be valuable to establish 
the repeatability of Myers et al’s short procedure. Considering the wide limits of agreement in 
relation to awake ambulatory blood pressure (limits of agreement –31.9 to 36.6 mmHg,22 where 
30-minute OBPM compared to daytime ambulatory blood pressure revealed limits of –19 to 19 
mmHg13), one may assume that the repeatability of their short procedure will not be as good 
as the present longer procedure. The differences between automated measurements with the 
patient alone in an examining room and standardized measurements seem to depend on the 
baseline blood pressure level of the study population; mean automated blood pressure was 
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142/80 mmHg in an outpatient clinic population (difference 20/5mmHg)10 and 115/71 mmHg in 
an open population study (difference 3/3 mmHg).23 The mean automated blood pressure of the 
present study population (134/84mmHg) was intermediate compared to the abovementioned 
studies, with the differences also intermediate. This is in line with the observation in the present 
study that differences are related to blood pressure level (Figures 1a and b). To the authors’ 
knowledge, data on the repeatability of any serial AOBPM were lacking until now. This is 
unfortunate because study of repeatability should be part of every validation procedure.14 The 
relevance of repeatability was underlined recently by Palatini et al, who reported that ABPM 
only predicted end-organ damage in subjects with reproducible recordings.24 In the absence 
of data on the repeatability of serial AOBPM, data in the present study were compared with 
reproducibility studies of 24-hour ABPM. In a study in 508 hypertensive patients,24 the SDD of 
24-hour ABPM was 8.3/6.4 mmHg. Stergiou et al reported an SDD of 8.3/5.6 mmHg for 24-hour 
ABPM; the SDD of the awake 24-hour ABPM was 10.0/6.6.25 In this last-mentioned article, the 
SDD for clinic blood pressure measurement was 11.0/6.6 mmHg,25 comparable to the SDD 
reported in the present study for standardised OBPM (10.9/6.3 mmHg). This study revealed that 
30-minute OBPM had a good repeatability, as the difference between visits 1 and 2 was less 
than 5 mmHg and the SDD (9.5/5.3 mmHg) was in agreement with above-mentioned studies 
concerning the repeatability of 24-hour ABPM. 
Implications for practice and research
The results of this study demonstrate the potential of 30-minute OBPM to reduce measurement 
bias and ‘white-coat effect’ in the office, without the need for ambulatory techniques. Combined 
with the authors’ previous work, a 30-minute OBPM is suggested to be a valid, office-based 
alternative to daytime ABPM or home blood pressure measurement, in attempting to determine 
one’s true blood pressure status. Meanwhile, the authors realise that 30- minute OBPM cannot 
replace several, relevant features that are unique for 24-hour ABPM, like measurement of 
blood pressure variability and nighttime blood pressure. Myers has already suggested how to 
implement the use of serial AOBPM in daily practice.26 He advocates using the same reference 
value for the diagnosis of hypertension as in home blood pressure monitoring or daytime 
ABPM (135/85 mmHg). The author’s previous finding that 30-minute OBPM outcome agreed 
well with daytime values of ABPM supports our proposal.13 Further research should focus on 
the comparison of serial AOBPM with home blood pressure measurement and on the optimal 
measurement duration. In addition, implementation studies on cost-effectiveness are required. 
In conclusion, 30-minute office blood pressure measurement resulted in lower readings than 
standardised office blood pressure measurement and had a better repeatability. The favourable 
repeatability and the lower values of 30-minute OBPM are promising for its value in blood 
pressure management in general practice. 
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Table 1. Characteristics of subjects  
Table 2. Blood pressure results (Δ = difference) 
OBPM = office blood pressure measurement; 
SD = standard deviation; 
SDD = standard deviation of the difference
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Figure 1a. Comparison of systolic blood pressures: Bland and Altman plot of difference between 
standardized systolic office blood pressure and 30-minute systolic office blood pressure against 
their mean (first visit)
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Figure 1b. Comparison of diastolic blood pressures: Bland and Altman plot of difference 
between standardized diastolic office blood pressure and 30-minute systolic office blood 
pressure against their mean (first visit)
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Figure 2a. Repeatability of standardized OBPM: Bland and Altman plot of difference between 
standardized systolic office blood pressure of visit 1 and 2 against their mean
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Figure 2b. Repeatablity of 30-minute OBPM: Bland and Altman plot of difference between 
30-minute systolic office blood pressure of visit 1 and 2 against their mean
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Abstract
Background: Current office blood pressure measurement (OBPM) is often not executed 
according to guidelines and cannot prevent the white-coat effect. Serial, automated, oscillometric 
OBPM has the potential to overcome both these problems. 
Objective: To validate a 30-minute OBPM through a method comparison with daytime ambulatory 
blood pressure.
Methods: Patients referred to a primary care diagnostic center for 24-hour ambulatory blood 
pressure monitoring (ABPM) had their blood pressure measured using the same validated 
ABPM device for both ABPM and 30-minute OBPMs. During 30-minute OBPM, blood pressure 
was measured automatically every 5 minutes with the patient sitting alone in a quiet room. The 
mean 30-minute OBPM (based on t = 5 to t = 30 minutes) was compared with mean daytime 
ABPM using paired t tests and the approach described by Bland and Altman on method 
comparison.
Results: We analyzed data from 84 patients (mean age 57 years; 61% female). Systolic and 
diastolic blood pressures differed from 0 to 2 mm Hg (95% confidence interval, –2 to 2 mm Hg 
and from 0 to 3 mm Hg) between mean 30-minute OBPM and daytime ABPM, respectively. The 
limits of agreement were between –19 and 19 mm Hg for systolic and –10 and 13 mm Hg for 
diastolic blood pressures. Both 30-minute OBPM and daytime ABPM classified normotension, 
white-coat hypertension, masked hypertension, and sustained hypertension equally.
Conclusion: The 30-minute OBPM appears to agree well with daytime ABPM and has the 
potential to detect white-coat and masked hypertension. This finding makes 30-minute OBPM a 
promising new method to determine blood pressure during diagnosis and follow-up of patients 
with elevated blood pressures.
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Introduction
The Framingham and the SCORE (systematic coronary risk evaluation) risk functions, both 
developed to assess the risk of cardiovascular disease, are based on standardised office 
blood pressure measurements (OBPMs).1,2 Despite guidelines that advocate the relevance of 
well-executed, standardised OBPM to prevent several forms of bias,3,4 it is well known that 
most caregivers do not execute OBPM strictly according to these guidelines.5,6 In addition, up 
to one-quarter of patients is prone to the white-coat effect (in which patients exhibit elevated 
blood pressure in a clinical setting but not in other settings), which influences cardiovascular 
risk profiling as well.7,8 This white-coat effect cannot be overcome by standardised OBPM. As 
a consequence, the determined cardiovascular risk will be incorrect in an estimated 25% of 
patients and may lead to under- or overtreatment. To enable a more precise determination of 
cardiovascular risk, OBPM should be free from (observer) bias and the white-coat effect. The 
measurement should be uniform, easy to execute correctly for all types of health care personnel 
(doctors, practice assistants, practice nurses, research assistants, etc), and straightforward 
to implement in daily practice. Fortunately, since the introduction of automated, oscillometric 
blood pressure measurement devices, this ideal can be met. Oscillometric devices are readily 
available in primary care and are used for 24-hour ambulatory blood pressure monitoring 
(ABPM) and home blood pressure monitoring.1,3 Guidelines have started to recommend the 
use of 24-hour ABPM and home blood pressure monitoring primarily for the detection of the 
white-coat effect.1,4 Although both these types of monitoring eliminate most types of observer 
bias and the white-coat effect, 24-hour ABPM is costly and not suitable for all types of patients; 
up to 50% of patients report it is a nuisance or results in disturbed sleep.9 With home blood 
pressure monitoring, patients are reported to be noncompliant with measurements or self-
report of blood pressures.10 There is a small but growing body of evidence to support a new 
method of office measurements in which a series of automated measurements is taken with the 
patient sitting alone in a quiet room (serial automated OBPM). The scarce, available research 
comes predominantly from one research group that used a validated oscillometric office blood 
pressure device able to be set at measurement intervals of 1 minute or more for a duration of 5 
to 10 minutes. With this protocol the white-coat effect was practically eliminated.11,12 
Meanwhile we developed a protocol that enables practices or primary care diagnostic centers 
to use a 24-hour ABPM device for serial automated OBPM. To our knowledge no previous 
research has studied using this protocol. A growing number of practices and diagnostic centers 
already possess 1 or more 24-hour ABPM devices. Using a 24-hour ABPM device for serial 
automated OBPM can be cost saving, and the device is user friendly, as clinic staff are already 
familiar with it. Validating our protocol may contribute to further acceptance of serial automated 
OBPM. As a first step in the process of validation, using a study sample of patients drawn from 
a family medicine population, we compared blood pressures determined using a protocol of 
serial measurements while patients were sitting for a mean of 30 minutes (30-minute OBPM) 
with their mean daytime ABPMs.
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Methods
Design, Setting, and Participants
We invited all patients aged 18 years or older who were referred by their family physician from 
October 2008 until February 2009 for a 24-hour ABPM to a diagnostic center that primarily 
supports family practices to participate in this comparative study. Reasons for referral were 
obtained from routinely used referral forms. Known atrial fibrillation, irregular pulse, pregnancy, 
and night shift work were exclusion criteria. After informed consent a 30-minute OBPM took 
place directly before a 24-hour ABPM. Ethics approval was not required, as declared by the 
local Medical Ethics Committee of the RUNMC (Central Committee on Research involving 
Human Subjects, Arnhem-Nijmegen, the Netherlands).
Blood Pressure Monitors and Measurements
A Welch Allyn Cardioperfect 6100 oscillometric blood measurement device (Welch Allyn 
Protocols, Inc, New York, New York) was used for both the 30-minute OBPM and the 24-hour 
ABPM. This device is equivalent to the validated SunTech Medical Oscar 2 device (SunTech 
Medical, Inc, Morrisville, North Carolina, and Eynshm, Oxfordshire, England; declaration of 
equivalence form13 available upon request).14 For each patient, the same device was used for 
both measurements. The devices are calibrated annually. All 30-minute measurements took 
place between 11 AM and 3 PM in a quiet room at the diagnostic center. The patient was 
sitting still 5 minutes before and during the 30-minute OBPM. The patient sat in a chair with a 
supported back, arm at heart level, and both feet resting flat on the floor. Blood pressure was 
measured on the nondominant arm at 5-minute intervals for a total of 8 measurements. The 
first measurement was a test measurement during the installation of the patient. The second 
measurement was the start of the 30-minute period; the researcher (I.E.B.) left the room after 
this measurement proved to be successful (no error reading). Previous research has shown that 
in serial measurements blood pressure can decline substantially in the first 10 minutes before it 
stabilizes.15,16 We therefore chose to exclude the first 2 measurements for the determination of 
the mean 30-minute OBPM. Thus we define 30-minute OBPM to be the mean blood pressure 
calculated from the 6 measurements taken at 5-minute intervals from t = 5 to t = 30 minutes. If 
more than 1 of these 6 measurements was erroneous (defined as an “error” reading given by 
the device), the entire case was excluded for analysis. To underpin our choice for a 30-minute 
period of measurements, we compared the mean 30-minute OBPM with the means of several 
shorter time periods, using the acquired data on 30-minute OBPM and recalculated these data 
to means based on 2 to 5 measurements. We then compared these means with the mean 
30-minute OBPM using paired t tests. The 24-hour ABPM was set at 20-minute intervals from 7 
AM to 11 PM and at 1-hour intervals from 11 PM to 7 AM. Blood pressure was monitored on the 
same arm as during the 30-minute OBPM. Patients were instructed to perform their usual daily 
activities but to stop moving and be silent during measurements. The mean daytime ABPM 
was calculated from the readings of 9 AM to 9 PM.3 Only patients with 15 or more successful 
daytime readings were included. Patient instructions and application of the monitors were 
performed by the same experienced researcher (I.E.B.), trained in the procedures of blood 
pressure measurement, using a standardised protocol based on the American Heart Association 
guidelines.4
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Classification of Hypertension Subtype
As an indication for the diagnostic value, we compared the 30-minute OBPM with the daytime 
ABPM in classifying 4 groups of blood pressure subtypes: normotension (office blood 
pressure <140/90 mm Hg and daytime ABPM or 30-minute OBPM <135/85 mm Hg); white-
coat hypertension (office blood pressure ≥140/90 mm Hg and daytime ABPM or 30-minute 
OBPM <135/85 mm Hg); masked hypertension (office blood pressure <140/90 mm Hg and 
daytime ABPM or 30-minute OBPM ≥135/85 mm Hg), and sustained hypertension (office blood 
pressure ≥140/90 mm Hg and daytime ABPM or 30-minute OBPM ≥135/85 mm Hg). In the 
absence of usual care office blood pressure measurements, we defined office blood pressure 
as the mean of the first 2 measurements of the 30-minute OBPM.
Sample Size
In the absence of international consensus criteria, we deemed a mean difference of 5 or more 
mm Hg between both types of measurements in the same patient to be of clinical relevance. 
Detection of blood pressure differences smaller than 5 mm Hg is seriously hampered by the 
biologic variation of blood pressure.17,18 With a 2-sided α of .05, a power of 90%, and a standard 
deviation of the difference of 15 mm Hg, a sample size of 81 would allow detection of a difference 
of 5 mm Hg or more.
Statistical Analysis
We calculated the difference between the mean daytime ABPM and the mean 30-minute blood 
pressure, as well as the standard deviation of the difference. Results are presented for systolic 
and diastolic blood pressure and for mean arterial pressure. Although mean arterial pressure 
is not a measure commonly used in primary care, we present it because it is measured by 
oscillometric devices to calculate the values of the systolic and diastolic blood pressure. The 
means of the daytime ABPM and the 30-minute blood pressures were compared using a paired 
t test. Bland-Altman plots were constructed to further evaluate agreement of both means. 
The limits of agreement in these plots were derived from the standard deviation of the mean 
difference between both measurements using the following formula: mean difference  +/- 1.96 
× standard deviation of the mean difference.19 
Pearson’s correlation was determined to study whether a difference between the means would 
relate to the magnitude of the blood pressure. Log transformation would be applied in case 
of dependence.20 We applied McNemar-Bowker test to determine whether the same patients 
who were categorised by 30-minute OBPM into 1 of the 4 subgroups of the hypertension 
classification were similarly categorised by the mean daytime ABPM. We used the SPSS version 
14.0 software package (SPSS Inc, Chicago, Illinois) for all analyses.
Results
Of 117 patients asked to participate, 18 patients declined, and 3 patients were excluded (2 with 
known atrial fibrillation, and 1 with irregular pulse at examination). Of 96 patients included, 6 
measurements exceeded the predefined number of erroneous readings; in 5 patients a problem 
occurred with cuff fitting during the 24-hour ABPM, and 1 patient was disturbed during the 
30-minute OBPM, leaving 84 patients for the final analysis. The characteristics of these patients 
58
chapter four
are shown in Table 1. Figure 1 shows that systolic blood pressure declines substantially in 
the first 15 minutes before reaching a plateau phase. We observed exactly the same course 
for diastolic blood pressure (data not shown). The mean 10-minute OBPM (mean of third and 
fourth measurements) is modestly but not significantly higher than the mean 30-minute OBPM 
(142/84 mm Hg vs 141/84 mm Hg; P = .1 and .7, respectively). No differences were found 
for mean 15-, 20-, and 25-minute OBPMs compared with the mean 30-minute OBPM. The 
mean blood pressure levels, the difference between the means, and the standard deviation of 
the difference of the daytime ABPM and the 30-minute blood pressure levels are depicted in 
Table 2. The limits of agreement were between –19 and 19 mm Hg for systolic blood pressure, 
between –10 and 13 mm Hg for diastolic blood pressure, and between –13 and 16 mm Hg for 
mean arterial pressure.
Figures 2a, 2b, and 2c plot the difference between the 30-minute OBPM and the daytime ABPM 
against mean blood pressure. The difference proved to be related to the magnitude of the mean 
blood pressure for systolic blood pressure, but not for mean arterial pressure and diastolic 
blood pressure (Pearson correlation coefficient r = 0.27, P = .01; r = 0.17, P = .13; and r = 
0.05, P = .64, respectively).
As shown in Table 3, the 30-minute OBPM classified patients into the 4 subgroups of hypertension 
(as mentioned in the method section) similarly to daytime ABPM. There was no significant 
difference in classification of patients between both measurements (P = .22); 87% of patients 
were classified similarly.
Discussion
We have reported a difference of less than 2 mm Hg, with a standard deviation of the difference 
of less than 10 mm Hg for mean arterial pressure and systolic and diastolic blood pressure 
of the mean 30-minute OBPM compared with the mean daytime ABPM using the same blood 
pressure monitoring device for both types of measurement. The limits of agreement were 
comparable to other blood pressure method comparison studies. In addition, 30-minute OBPM 
seems to be able to detect white-coat hypertension as well as daytime ABPM does.
Our Results in Perspective of Previous Research
Although in our study no clinical relevant systematic difference was detected between 30-minute 
OBPM and daytime ABPM, the limits of agreement show that at the individual level, substantial, 
clinical relevant differences can occur (Figures 2a-c). Ideally in comparative studies the reference 
measurement has an excellent reproducibility.20 In blood pressure measurement, however, this 
reproducibility is always limited by the relatively large intrapersonal biologic variation of blood 
pressure. Consequently, any comparative study on blood pressure measurements will result 
in relatively wide limits of agreement. The limits of agreement in our study did not exceed 
even those of well-executed reproducibility studies (eg, with 24-hour ABPM).18,21 Accordingly, 
30-minute blood pressure readings are preferred to other types of office-based blood pressure 
measurements.22 Although it is known that conventional OBPMs executed in complete 
accordance with guidelines may reach results similar to those of ABPMs,23 daily practice over 
the last decades has proved that one can be skeptical about ever bridging the gap between 
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theory and daily practice. No previous studies have aimed at comparing mean 30-minute blood 
pressures with mean daytime ambulatory blood pressure in a primary care setting using the 
same measurement device for both types of measurement.
There has been some research showing that mean 4- to 10-hour blood pressure was 
comparable to mean daytime ambulatory blood pressure.24,25 In a recent study, Culleton et 
al reported on the use of a mean 25-minute (4-minute interval) oscillometric blood pressure 
measurement to reduce white-coat effect.26 Mean 25-minute blood pressure appeared to be 10 
mm Hg lower than daytime ABPM. Differences, however, in the primary objective of the study, 
the study population, and the period of rest before start of measurement obstruct reasonable 
comparison with our results.
Our results are in agreement with data from Myers et al, where the automated office measurement 
proved to be 2 mm Hg lower than daytime ABPM.12 Their study population was almost similar 
to ours, but their blood pressure measurement protocol differed considerably (5 or 10 minutes, 
apparently without a prior rest period). In contrast to Myers et al, we used 1 device for both the 
office and the ambulatory measurement. In this way, we excluded a potential source of bias 
when comparing the 2 measurement methods. We purposely chose to validate a protocol with 
the use of an ABPM device because we anticipate that in most industrialized countries these 
devices will soon become standard equipment in family physicians’ offices. With the 30-minute 
protocol, practices can than use 1 type of device (and 1 type of software) for both office and 
ambulatory measurements. The 5-minute measurement interval in our protocol was chosen 
because the minimum measurement interval of most, if not all, ambulatory devices can be set at 
least at 5 minutes. As a consequence, with the same number of measurements, this minimum 
interval results in a longer measurement period than the 10 minutes studied by Myers et al. Our 
results showed, however, that serial measurements for 10 minutes after a 5- to 10-minute rest 
period may be sufficient; future research is needed to underline this possibility.
Strengths and Limitations
Our study has several strengths. It was performed in a primary care setting—the setting where 
high blood pressure is most often diagnosed and managed. Blood pressure measurements 
were executed according to clear and well-described protocols that can be easily implemented 
in daily practice using existing blood pressure measurement devices. For logistic reasons we 
were unable to randomize the order in which 30-minute OBPM and ABPM took place. As a 
consequence, a regression to the mean could have influenced the results of our study. The 
30-minute OBPM, however, was not used as a selection criterion to undergo 24-hour ABPM, 
and the mean 30-minute measurement was determined excluding the first measurement.
Our definition of a successful daytime ABPM was more lenient than the consensus-based 
definitions of most guidelines. To understand whether this discrepancy would influence results, 
we reanalyzed our data from 64 patients using the cutoff as defined by O’Brien et al3 and found 
the results to be consistent with those reported here (data not shown). The study population 
consisted of hypertensive patients in usual care family practice, some of whom were taking 
antihypertensive medications. Although in theory treatment for hypertension may have had 
an effect on the study outcome, in their method comparison study, Little et al found that, in 
a family practice–based population, treatment does not bias results.22 The mean difference 
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between 30-minute OBPM and daytime ABPM was related to the magnitude of the blood 
pressure. This relation is common in blood pressure research, and if this relation is strong, it 
seems reasonable to report conclusions separately for both hypertensive and normotensive 
patients. In our study, however, the observed correlations were very small and do not affect our 
conclusions. We realize that the outcome of our study depends in part on the population under 
study, its sample size, and the setting. For instance, that our 30-minute OBPM was executed in 
a single primary care diagnostic center rather than in actual family practices may have affected 
the results, because of a potential difference in white-coat effect between settings. Recently, 
however, Ogedegbe et al showed that although setting can be a factor, the role of the physician 
is most relevant.27
Future Perspectives
Currently, detection of the white-coat effect is the main and most evidence-based indication for 
the use of 24-hour ABPM or home blood pressure monitoring, and guidelines formulate with 
caution about other possible indications.1,3-4 We believe that automated OBPM (such as the 
30-minute OBPM) is a valid, useful, office-based alternative to daytime ABPM or home blood 
pressure monitoring for this indication. Moreover and contrary to the more laborious home 
blood pressure monitoring and 24-hour ABPM, 30-minute OBPM could be a convenient way to 
follow up high blood pressure findings. Although 30-minute OBPM and home blood pressure 
monitoring are theoretically interchangeable with regard to indication and interpretation, the 
same cannot be said for 24-hour ABPM. Twenty-four hour monitoring gives unique information 
about the diurnal blood pressure pattern (dipping or nondipping), blood pressure variability, 
and mean night blood pressure. It is unclear, however, whether these data can be used to 
improve cardiovascular risk management, and if so, how these variables should be used and 
interpreted in family medicine. Improvement of office measurement techniques can already 
benefit patients substantially, particularly in family medicine. Very recently an algorithm has 
been proposed for diagnosing hypertension using serial automated OBPM.24
The 30-minute OBPM agrees well with daytime ABPM and has limits of agreement comparable 
to other method comparison studies of blood pressure. It appears to classify blood pressure 
status of patients as well as daytime ABPM. Accordingly, this new method of office blood 
pressure measurement can potentially enable family physicians to overcome well-known 
problems when measuring usual blood pressure, such as observer bias and the white-coat 
effect. Additional research is needed to determine the reproducibility of the 30-minute OBPM 
and its agreement with usual office and home-based blood pressure measurements.
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Table 1. Characteristics of Study Population   
ABPM = 24-hour ambulatory blood pressure monitoring
ABPM = ambulatory blood pressure monitoring; 
CI = confidence interval; 
DBP = diastolic blood pressure; 
MAP = mean arterial pressure; 
OBPM = office blood pressure measurement; 
SBP = systolic blood pressure; 
SDD = standard deviation of the difference of the mean;
† P = .03; ‡ P = .008;
Note: Because of rounding, figures may not add up correctly 
Table 2. Blood Pressure Levels for Daytime ABPM and 30-Minute OBPM  
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Table 3. Comparison of the number of patients classified by hypertension subtypes between 
30-minute OBPM and daytime ABPM 
HT = hypertension; 
WCH = white coat hypertension
Note: There were 87% of patients similarly classified by both 30-min OBPM and daytime ABPM
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Figure 1: Course of mean systolic blood pressure during 30 minutes of measurement  
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Figure 2a. Bland-Altman plot of difference in mean arterial pressure between 30-minute OBPM 
and daytime ABPM against mean mean arterial pressure
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Figure 2b. Bland-Altman plot of difference in systolic blood pressure between 30-minute OBPM 
and daytime ABPM against mean systolic blood pressure
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Figure 2c. Bland-Altman plot of difference in diastolic blood pressure between 30-minute OBPM 
and mean daytime ABPM against mean diastolic blood pressure
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Abstract
Background: Recently it was demonstrated that sitting 30-minute automated office blood 
pressure measurement (30-min OBPM) agreed well with daytime ABPM and classified subtypes 
of blood pressure similarly. Until now it is unclear if supine 30-min OBPM could be considered 
as an alternative for sitting 30-min OBPM.
Objective: To validate a supine 30-minute OBPM through a method comparison with daytime 
ambulatory blood pressure.
Methods: In patients referred to two primary care diagnostic centers for 24-hour ambulatory 
blood pressure monitoring (ABPM) we used the same, validated ABPM device for both 
measurements. During supine, 30-min OBPM blood pressure was measured automatically 
every five minutes, with the patient lying still, alone in a quiet room. Mean 30-min OBPM (based 
on t=5 to t=30 minutes) was compared with mean daytime, nighttime and 24-hour ABPM using 
paired t-tests and the approach described by Bland and Altman on method comparison.
Results: Data of 96 patients (mean age 60 years; 58% female) were analyzed. Systolic blood 
pressure differed -1 (-4 to 2), 17 (14 to 20) and 2 (-1 to 4) mmHg between supine 30-min 
OBPM and daytime, nighttime and 24-hour ABPM respectively (95% CI). Supine 30-min 
OBPM classified normotension; white coat hypertension; masked hypertension and sustained 
hypertension equal to daytime ABPM.
Conclusions: Supine 30 min OBPM agreed well with daytime ABPM also in classifying subtypes 
of blood pressure like white coat and masked hypertension. 30 minutes supine blood pressure 
does not resemble blood pressure while sleeping. Although we prefer sitting 30-min OBPM, 
the results of this study suggest that supine 30-min OBPM presents an alternative method to 
determine blood pressure in the office and can be used when patients’ preference or physical 
condition would make it more appropriate.
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Introduction
There is a small but growing body of evidence that demonstrates the value and relevance of 
serial automated office blood pressure measurements (AOBPM).1, 2
For AOBPM, measurement devices can be used that are purposely built for this task (e.g. 
BPTru, Microlife WatchBP Office). These devices are capable to measure blood pressure with 
relatively small time intervals down to 15 seconds.3, 4
We hypothesized that ambulatory blood pressure devices could also be convenient to use 
for AOBPM. In a validation project consisting of three studies we validated an AOBPM with 
duration of 30 minutes (30-min OBPM). In two studies we demonstrated that sitting 30-min 
OBPM agreed well with both daytime ambulatory and standardized office blood pressure 
measurement. Reproducibility proved to be better than that of standardized office BPM.5, 2 This 
paper reports the validation of supine 30-min OBPM. 
While in older guidelines supine and sitting blood pressure measurements were considered 
to be interchangeable 6-8 in most recent guidelines the position of supine measurements is no 
longer mentioned 9, 10, or considered for certain subgroups.11 Predominantly in hospital settings, 
however, supine AOBPM is used as primary blood pressure measurement. Reasons to maintain 
supine measurements are tradition, inability for subgroups of patients to sit (still) for several 
minutes, better standardisation of the arm position and management of the patient flow in 
outpatient clinics. One could argue that supine blood pressure measurements may compare 
with nighttime blood pressure levels and would thus underestimate true daytime blood pressure. 
As part of the validation of 30-min OBPM we therefore studied how supine 30-min OBPM agrees 
with daytime and nighttime ABPM. 
Methods
Design, setting and participants 
In this comparative study patients aged 18 years or older who, over a six month period, were 
referred to two primary care based diagnostic centers for 24-hour ambulatory blood pressure 
monitoring (24-hour ABPM) by their family physician were invited to participate. Reasons for 
referral were obtained from routinely used referral forms.
Known atrial fibrillation, irregular pulse, pregnancy, working in night-shifts and four or more 
alcohol consumptions in the evening prior to the 24-hour ABPM were exclusion criteria. After 
informed consent a 30-min OBPM took place directly prior to 24-hour ABPM. Ethics approval 
was not required, as declared by the local Medical Ethics Committee of the RUNMC (Central 
Committee on Research involving Human Subjects, Arnhem-Nijmegen, The Netherlands).
Blood pressure monitors and measurements
OSCAR 2 (SunTech Medical Inc, Morrisville, USA) oscillometric blood pressure measurement 
devices were used for both the 30 min OBPM and the 24-hour ABPM.12 For each patient, the 
same device was used for both measurements. The devices used are calibrated annually.
All 30 minutes measurements took place between 1.00 and 4.00 p.m. in a quiet room at the 
diagnostic centre. The patient was lying in supine position with a small neck rest five minutes 
prior to and during the 30-min OBPM. The patient was instructed to lie still for the entire 
74
chapter five
measurement period and leave both arms parallel to the body. Blood pressure was measured 
at the non-dominant arm with a five minutes interval for a total of seven measurements. The first 
measurement (t=0) was after 5 minutes of rest; the researcher (LL or FD) left the room after this 
measurement proved to be successful (no error reading). We have defined 30-min OBPM to 
be the mean blood pressure calculated from the six measurements taken at 5 minutes intervals 
from t=5 to t=30 minutes.2 If more than one of these six measurements was erroneous (defined 
as an “error” reading given by the device), the entire case was excluded for analysis. Although 
we know of at least one ABPM device with a minimum measurement interval of as little as two 
minutes, we have chosen for five minute intervals to increase generalisability and validate a 
protocol that can be executed by several types of ABPM devices. 
The 24-hour ABPM was set at 20 minutes intervals from 7 a.m. to 11 p.m. and at a one hour 
interval from 11 p.m. to 7 a.m. Blood pressure was monitored at the same arm as during 30-min 
OBPM. Patients were instructed to perform their usual daily activities but to stop moving and 
be silent during measurements. The mean daytime ABPM was calculated from the readings 
of 9 a.m. to 9 p.m.; mean nighttime ABPM from the readings between 0 a.m. and 6 a.m. and 
mean 24-hour ABPM from all available readings.13, 14 Patient instructions and application of 
the monitors were performed by the same experienced researchers (LL, FD), trained in the 
procedures of blood pressure measurement, using a standardised protocol based on the AHA 
guidelines.15
Classification of hypertension subtype
In the current study we did not obtain standardized office blood pressure measurements. To 
enable an indication of the diagnostic value of supine 30-min OBPM we therefore defined office 
blood pressure to be the first measurement of the 30-min OBPM. Subsequently, we compared 
supine 30-min OBPM with daytime ABPM in classifying four groups of blood pressure subtypes: 
normotension (office blood pressure <140/90 mmHg and daytime ABPM or 30-min OBPM 
<135/85 mmHg); white coat hypertension (office blood pressure ≥ 140/90 mmHg and daytime 
ABPM or 30-min OBPM < 135/85); masked hypertension (office blood pressure < 140/90 
mmHg and daytime ABPM or 30-min OBPM ≥ 135/85 mmHg) and sustained hypertension 
(office blood pressure ≥ 140/90 mmHg and daytime ABPM or 30-min OBPM ≥ 135/85). 
Sample size
We deemed a mean difference of five or more mmHg between both types of measurements 
in the same patient to be of clinical relevance. Detection of blood pressure differences smaller 
than five mmHg is seriously hampered by the biological variation of blood pressure.16, 17 With 
a two-sided α of 0.05, a power of 90%, and a standard deviation of the difference (SDD) of 15 
mmHg a sample size of 81 would allow detection of a difference of 5 mmHg or more.
Statistical analysis
The difference between 30-min OBPM and daytime, nighttime and 24-hour ABPM was 
calculated, as well as the SDD. The means of daytime, nighttime and 24-hour ABPM and 30-
min OBPM were compared using a paired t-test. Bland-Altman plots were constructed to further 
evaluate agreement. 
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The limits of agreement in these plots were derived from the standard deviation of the mean 
difference between both measurements using the formula: mean difference +/- 1.96 * standard 
deviation of the mean difference.18 We applied McNemar-Bowker test to determine whether 
the patients, categorized by 30-min OBPM in one of the four subgroups of the hypertension 
classification, were similarly categorised with mean daytime ABPM. We used SPSS version 14.0 
software (SPSS, Inc) package for all analyses.
Results
We asked one hundred and twenty consecutive patients to participate; 14 patients declined, 
no patients were excluded. Of 106 included patients three 30-min OBPM and three 24-hour 
ABPM’s exceeded the predefined number of erroneous readings, in 3 patients ABPM data were 
not stored/saved correctly and turned out to be missing and in one patient a problem occurred 
with cuff-fitting leaving 96 patients for the final analysis. The characteristics of these patients 
are shown in Table 1. Mean blood pressure levels and the differences between the ambulatory 
and 30-min OBPM means are depicted in table 2. While differences between 30-min OBPM and 
daytime or 24- hour ABPM are within 2 mmHg, nighttime ABPM was between 10 and 20 mmHg 
lower than 30-min OBPM.
Figures 1a, b and c plot the mean difference of systolic blood pressure between the 30-min 
OBPM and daytime, night time and 24-hour ABPM against the mean blood pressure. The limits 
of agreement were between -25 and +23 mmHg; -12 and 46 mmHg and -22 and 26 mmHg 
for figures 1a-c respectively.  Plots for diastolic blood pressure and MAP show a similar pattern 
(data not shown).
In table 3 it is shown that 30-min OBPM classified patients in the four subgroups of hypertension 
(as mentioned in the method section) similar to daytime ABPM. There was no significant 
difference in classification of patients between both measurements (p = 0.37); 82% of patients 
were classified similarly.
Discussion
Systolic and diastolic blood pressure did not differ between supine 30-min OBPM and daytime 
ABPM (mean differences smaller than 2 mmHg). In contrast, the difference with nighttime ABPM 
was substantial (17/13 mmHg; p < 0.001). Supine 30-min OBPM classified normotension; white 
coat hypertension; masked hypertension and sustained hypertension equal to daytime ABPM.
Results in context of previous research
We are unaware of previous publications dealing with supine serial automated OBPM. Several 
publications of Myers et al have demonstrated the relevance of serial automated OBPM in 
sitting position, but data on lying patients are lacking.19-21   
Compared to our findings with sitting 30-min OBPM 2 we could not observe a clinically relevant 
difference neither in the blood pressure readings nor in the classification of blood pressure in 
different subtypes (like white coat hypertension). Although a direct comparison between sitting 
and supine 30-min OBPM is lacking, our current findings at least suggest that sitting and supine 
measurements are interchangeable.
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The number of studies dealing with the influence of body and arm position on blood pressure 
is small and seems to be inconclusive. Netea et al demonstrated that with the arm exactly 
positioned at heart level systolic and diastolic supine oscillometric blood pressure was 6 and 5 
mmHg higher than sitting blood pressure respectively.22 In studies where the arm position was 
not corrected sitting was (almost) equal to supine systolic blood pressure (0-2 mmHg higher). 
Sitting diastolic blood pressure could differ from supine in a range from +2 to -6 mmHg.23-
26 In the last decade only two studies of sufficient quality dealt with supine measurements. 
One study demonstrated that supine blood pressure was 9/3 mmHg higher than sitting, but 
information about arm position was lacking and there was no correction for the fixed sequence 
of measurements.27 Braam et al showed that blood pressure was 3/1 mmHg higher in supine 
than in sitting patients with arms exactly at heart level, and 2 mmHg higher systolic but 2 mmHg 
lower diastolic with arms not positioned at heart level.28 From the presented data we conclude 
that body position influences blood pressure independently from arm position but this influence 
is small and appears to be of minor clinical relevance.
It is well described that blood pressure has a diurnal rhythm which is not based on an underlying 
circadian rhythm but more so on arousal and (sympathetic) activity.29-31 In our study the 
difference between supine 30-min OBPM and nighttime ABPM was considerable, while it was 
very small with daytime ABPM. This suggests that a 30 minute period of measurement during 
the day could be regarded more as part of normal daily activities than as the basal situation 
during sleep. Previous research already demonstrated that resting during daytime is not similar 
to sleep. In bed ridden patients due to a leg cast blood pressure was 25% higher during the 
day than during the night.32
Limitations
Supine blood pressure is not advocated in most guidelines and most prognostic data are based 
on sitting BP measurements. However, as discussed, consensus about the influence of body 
position on blood pressure appears to be lacking.
In our study we did not monitor whether patients fell asleep during supine 30-min OBPM. Our 
results, however, showed that mean 30-min OBPM agreed well with daytime and poor with 
nighttime blood pressure. Agreement with daytime ABPM was similar to the agreement of 
daytime ABPM with sitting 30-min OBPM.2 In the unlikely event that a patient would have fallen 
asleep directly after the observer left the room and in addition slept constantly to re-entry of the 
observer 30 minutes later, in theory the patient could have reached sleeping stage 2 which is 
reported to result in maximum 10% lower blood pressures than during wakefulness. This is half 
of the decline that occurs during sleeping stage 3-4.33, 34
For logistic reasons we were unable to randomize the order in which 30-minute OBPM and 
ABPM took place. As a consequence, a regression to the mean effect could have influenced 
the results of our study. However, the 30-minute OBPM was not used as a selection criterion to 
undergo 24-hour ABPM, and the mean 30-minute measurement was determined excluding the 
first measurement.
Despite some methodological limitations we still have chosen to determine hypertension 
subtypes, because we value to demonstrate practical implications of our findings. We used 
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the first measurement of 30-min OBPM as normal office measurement, which is likely to be not 
perfectly similar. In addition we classified white coat and masked hypertension in a population 
that was in part under antihypertensive treatment. The presented data should therefore be seen 
as indicative only.
Future perspectives
Although body position influences blood pressure this effect appears to be very small and 
of minor clinical relevance. In accordance with the most recent guidelines we prefer sitting 
blood pressure measurements over supine. If a supine measurement is nevertheless method 
of choice (e.g. because of patient inability or preference) supine 30-min OBPM seems to be a 
valid alternative for sitting 30-min OBPM. 
When combining the findings of this study with the results of sitting OBPM we can now conclude 
that 30-min OBPM is a robust method to measure blood pressure, with high potential for use in 
general practice. This makes it particular relevant to establish its clinical value in daily practice.21
In future studies we would like to establish the minimum and optimum requirements, with regard 
to a priori rest period, measurement interval and measurement time for a serial automated 
OBPM protocol and thus stimulating implementation of automated OBPM irrespective of the 
device used. In addition, data on the cost effectiveness of 30-min OBPM is needed. 
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Table 1. Characteristics of study population   
ABPM = 24-hour ambulatory blood pressure monitoring 
ABPM = ambulatory blood pressure monitoring; 
OBPM = office blood pressure measurement; 
SBP = systolic blood pressure; 
DBP = diastolic blood pressure; 
MAP = mean arterial pressure; 
CI = confidence interval; † p < 0.001; ‡ p < 0.05
Table 2. Mean blood pressures for 30-min OBPM, daytime, nighttime and 24-hour ABPM and 
mean differences between 30-min OBPM and ABPM
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Table 3. Comparison of the number of patients classified in the hypertension subtypes between 
30-min OBPM and daytime ABPM 
HT = hypertension; 
WCH = white coat hypertension; 
82% of patients are similarly labeled by both 30-min OBPM and daytime ABPM
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Figure 1a. Bland-Altman plot of difference between supine 30-min OBPM and daytime
ABPM systolic blood pressure against mean systolic blood pressure
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Figure 1b. Bland-Altman plot of difference between supine 30-min OBPM and nighttime
ABPM systolic blood pressure against mean systolic blood pressure 
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Figure 1c. Bland-Altman plot of difference between supine 30-min OBPM and 24-hour
ABPM systolic blood pressure against mean systolic blood pressure
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Abstract
Background: Population based hypertension control is suboptimal, despite widely available, 
cheap and effective treatment options. Patient tailored initiation of treatment may improve 
hypertension control rates. Previous studies exploring the use of patient characteristics as 
predictors of treatment response came with several methodological limitations and are not well 
transferable to everyday general practice – the setting were most patients with hypertension are 
diagnosed and treated.    
Objective: To study potential predictive patient characteristics to the response of two classes 
of antihypertensive drugs with different mechanisms of action in patients with newly diagnosed 
hypertension in primary care. 
Methods: We conducted a prospective, open label, blinded endpoint crossover trial in ten, Dutch 
general practices. 120 patients with a new diagnosis of hypertension identified in usual general 
practice entered the study. Most important exclusion criteria were use of antihypertensive 
medication and presence of cardiovascular co-morbidity. 98 patients (52% female; mean 
age 52 yrs) were eligible for per-protocol-analysis. Patients received 4 weeks of 12.5 mgr 
hydrochlorothiazide once daily and 4 weeks of 80 mgr valsartan once daily, each followed by 
a 4 week washout. The sequence of drugs was randomized. Age, sex and menopausal state 
were recorded at run in and 24-hour ambulatory blood pressure, office blood pressure, plasma 
renin concentration, NT-proBNP, potassium, estimated glomeral filtration rate, urinary albumin, 
body mass index and waist circumference at each regimen change. Blood pressure response 
was determined by 24-hour ambulatory blood pressure monitoring.
Results: Besides BMI -which was significantly related to the effect of valsartan (ß -0.63, p = 
0.04) - the studied variables were not predictive for blood pressure response. Individual systolic 
blood pressure response ranged from an increase by 18 mmHg to a decrease of 39 mmHg. 
Conclusions: We did not find predictors that could support personalised hypertension treatment 
in uncomplicated essential hypertension. Our findings are not in agreement with the theoretical 
framework used to support the current treatment recommendation of the NICE guideline on 
hypertension. 
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Introduction
Recent meta-analyses have demonstrated that on average all known classes of antihypertensive 
medication are equally effective in reducing blood pressure.1;2 However, several studies have 
confirmed what clinicians experience in daily practice: in individual patients treatment response 
can differ substantially from one antihypertensive class to the other.3;4
This finding supports the attractive possibility that predictive factors can be identified that 
determine the success rate of an antihypertensive drug. Application of such a predictive 
therapeutic strategy, able to predict the hypotensive response, might reduce polypharmacy, 
enhance treatment adherence and reduce costs.5;6 
Research in animals and humans suggests that several patient characteristics may have 
predictive qualities. All international guidelines on hypertension management advise to initiate 
treatment in patients of African or Caribbean descent with a diuretic or calcium channel 
blocker (CCB), because renin-angiotensin-aldosterone-system (RAAS) activity is relatively low 
in most of these patients.7-9 Besides ethnicity, other potential factors are plasma renin 4;10;11, 
NT-proBNP 3;12, potassium 13, estimated glomeral filtration rate (eGFR), urinary albumin, waist 
circumference 14, BMI 15, sex 16;17, age 18;19 and menopause.20   
Because hypertension is diagnosed and managed most often in general practice, studies on 
individual treatment response should ideally be performed in general practice based populations 
and reflect an age around 55-60 years, in which diagnosis is commonly made.21;22 Selection of 
predictive characteristics should preferably be based on the actual feasibility of implementation 
in daily general practice. Several clinical studies have tried to identify predictors of the individual 
blood pressure response to different classes of antihypertensive medication.3;4;11;23;24 However, 
extrapolation to current general practice is seriously limited for a number of reasons: some 
studies examined only patients younger than 55 years 3;4; all included predominantly male 
patients 3;4;11;23;24; some studies used only supine blood pressure measurements3;4 or studied 
diastolic blood pressures.3;11;23;24 In addition, in some studies identification of predictors was not 
the primary objective.3;4;24
We therefore decided to set up a study with the primary objective to identify predictors to the 
blood pressure response of two classes of antihypertensive drugs with different mechanisms 
of action (angiotensin receptor blocker (ARB) and diuretic) in a representative general practice 
population and with a set of potential predictors that are feasible to implement in the general 
practice setting.
Methods
Patients, design and setting
Patients with newly diagnosed hypertension, aged 18 – 65 years and listed in 10 general 
practices affiliated with the Radboud University Nijmegen Medical Centre 25 were screened 
for eligibility to participate in a prospective open label blinded end point (PROBE) 26 crossover 
study. Patients in whom the diagnosis of hypertension was confirmed and who gave written 
informed consent were included in the study. Exclusion criteria were use of antihypertensive 
medication, blood pressure higher than 210/110 mmHg, inability to speak or understand Dutch 
and presence of cardiovascular co-morbidity (diabetes mellitus, peripheral arterial disease, 
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ischemic heart disease, stroke, transient ischemic attack and atrial fibrillation). We excluded 
this last group because hypertension treatment algorithms differ from those in uncomplicated 
patients.7-9  
After a two week run-in period, patients used four weeks of hydrochlorothiazide 12.5 mg 
once daily and four weeks of valsartan 80 mg once daily.  The sequence of medication was 
randomized and each medication period was followed by a 4 week washout period (figure 1). 
At the run in and at the start and end of each medication or washout period we measured 24 
hour ambulatory blood pressure (24-hour ABP), office blood pressure (OBP), plasma renin 
concentration, NT-proBNP, plasma potassium concentration, eGFR, urinary albumin excretion, 
body mass index (BMI) and waist circumference. At the run in also age, sex and menopausal 
state were recorded. 
The study was approved by the local Medical Ethics Committee of the RUNMC (Central 
Committee on Research involving Human Subjects, Arnhem-Nijmegen, The Netherlands) and 
registered in clinicaltrials.gov under NCT00457483.
Blood pressure measurements
During the eligibility screening performed by the local staff of the general practices a confirmed 
diagnosis of hypertension (≥ 140/90mmHg) was based on the mean of blood pressure 
measurements taken at three different office visits. All practices were provided with two validated 
oscillometric office monitors (Stabil-O-Graph, I.E.M. GMBH, Stolberg, Germany).27 These 
monitors were exclusively used for study patients and were re-calibrated every two years. The 
office blood pressure measurements during the study were taken by practice nurses who were 
trained in the methodology of standardised blood pressure measurement.
All 24-hour ABP recordings were taken on week days and patients were asked to keep a 
standardised diary of daily activities. Practices used the same, validated 24-hour ABPM 
device (Mobil-O-Graph, I.E.M. GMBH, Stolberg, Germany).28 The measurement interval was 
20 minutes from 7 a.m. to 11 p.m. and 1 hr from 11 p.m. to 7 a.m. We defined the mean day 
ABPM from 9 a.m. to 9 p.m. and we used this measure as our primary blood pressure outcome. 
Only recordings with 70 % or more valid readings were used. Using the software of the ABP 
device, the display of the device was set not to show blood pressure values. Ambulatory blood 
pressure values were not communicated to the patient, prescribing physician and researcher 
until after completion of the study protocol.
Study variables and study medication
We selected demographic and biochemical variables that general practitioners commonly use 
or that are easily implemented in daily practice. All blood and urine samples were collected 
in the morning (before 12.30 pm) and analyzed at one primary care orientated diagnostic 
centre. Sample analyses were performed batch wise. The following laboratory tests were 
used: creatinine (CREA plus, Roche Diagnostics), renin (DSL-25100 ACTIVE Renin IRMA kit, 
Diagnostic Systems Laboratories), NT-proBNP (Elecsys, Roche Diagnostics), potassium (ISE 
Indirect, Roche Diagnostics), urine albumine (COBAS, Roche Diagnostics). 
Based on literature about equipotence, patients used 80 mg valsartan once daily and 12.5 mg 
hydrochlorothiazide once daily.29 These dosages also are in agreement with recommendations 
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of the Dutch guideline on cardiovascular risk management.30 Following the PROBE design, 
medication was not blinded for both patients and the prescribing general practitioners. We 
recorded compliance and adverse events with the use of standardised questionnaires. 
Statistical analyses and sample size calculation
First, we applied descriptive statistics to compare baseline patient characteristics of patients 
who completed the study with those who were lost to follow up. We used Pearson’s test for 
correlation to study the relation between the individual blood pressure responses of both 
medications. To visualise intra-individual responses of blood pressure to both medications we 
plotted all individual responses and linked the results of each patient.    
Next, we performed mixed model analyses (using a compound symmetry correlation matrix) to 
determine whether relevant carry-over, period and treatment effects occurred. 
In the final step, according to a per protocol analysis on those patients that had minimally 
completed the second medication period, we used univariate followed by manual forward 
multiple regression analysis with mean systolic blood pressure response (blood pressure at start 
of treatment minus blood pressure after 4 weeks of treatment) to either hydrochlorothiazide or 
valsartan as primary dependent variables. A negative blood pressure response implies a rise in 
blood pressure after treatment. Renin and NT-proBNP were modelled after log transformation. 
Although our study was not primarily powered for (post-hoc) subgroup analyses, we explored 
how results would alter in subgroups based on sex, the age used in the NICE guideline (<55 
years; or ≥ 55 years) and on renin and NT-proBNP tertiles.
In all analyses we considered a two sided p-value of < 0.05 to be significant. Statistical test 
were performed with SPSS version 16 (SPSS Inc, Chicago, Illinois). With 10 variables that in 
theory could all be part of the multiple regression model and with a minimum requirement 
of at least 10 observations per variable 31 a sample size of 100 patients was needed for final 
analyses. Taking loss to follow up in account we planned to include 140 patients.   
Results
Of 159 patients formally assessed for eligibility, 120 patients signed informed consent and 98 
patients were included in final analysis. Patient flow and loss to follow up are visualized in figure 
2. In Table 1 the main patient characteristics at baseline (start of the first medication period) are 
depicted. Figure 3 depicts the difference in systolic blood pressure response for each patient. 
This response ranged from -18 to 34 mmHg and -17 to 39 mmHg for hydrochlorothiazide and 
valsartan respectively. There was no correlation between the response to hydrochlorothiazide 
and valsartan (r = 0.02, p = 0.88). Repeated measures analyses demonstrated that there was 
no significant difference between the daytime ambulatory blood pressure values at the start 
of the first medication period and at the end of each washout period (figure 1). There was no 
difference in carry- over effect between both sequences of study medication. For systolic blood 
pressure we found no period effect, while for diastolic blood pressure the period effect was 
significant (1.8 mmHg, p = 0.04). Valsartan reduced blood pressure on average by 3/2 mmHg 
more than hydrochlorothiazide (p = 0.03).
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We did not find a single study variable to predict the systolic blood pressure response to 
hydrochlorothiazide (table 2). Table 3 depicts that with increasing BMI the response to valsartan 
decreased. Results were similar for diastolic blood pressure (data not shown).
Post hoc analysis (table 4) demonstrated that mean blood pressure reduction by valsartan 
in patients of 55 years and older was exactly the same as in younger patients (p = 0.99). 
Hydrochlorothiazide appeared to reduce blood pressure better in patients of 55 years and 
older, but the difference with younger patients was not significant (p = 0.17) In young patients 
valsartan reduced blood pressure significantly more than hydrochlorothiazide; in older patients 
a similar pattern was seen but the difference was not significant. Both study medications tended 
to reduce blood pressure more in women than in men. In women valsartan reduced blood 
pressure significantly more than hydrochlorothiazide; in men this difference was not significant. 
Although not significant, for each tertile of higher plasma renin concentration valsartan tended 
to reduce blood pressure more than hydrochlorothiazide. The effect of both medications did 
not differ significantly between tertiles. 
Discussion
In this study with newly diagnosed hypertensive patients in general practice plasma renin 
concentration, age, NT-proBNP, potassium, eGFR, urinary albumin, waist circumference, sex and 
menopausal state were not predictive for the response to either valsartan or hydrochlorothiazide. 
BMI weakly but significantly predicted the response to valsartan. 
Our study underlines results of previous crossover trials that were also unable to find convincing 
evidence for the use of predictors in antihypertensive management.3;4;23 While one study could 
not identify predictors (including plasma renin activity, catecholamines, age) for blood pressure 
response at all 3, another only found plasma renin activity to be a weak predictor (r = -0.40) for 
ACE-inhibition but not for ß blockade.4 Finally, in another trial plasma renin concentration and 
blood pressure response to ACE inhibitor were not related, while a weak association (r = 0.32) 
with a ß-blocker existed.23 Our study is the first to suggest a predictive role for BMI. However, 
the inverse relation with the response to valsartan is opposite to what we expected based on 
pathophysiological grounds.14;15 We do not exclude that our finding may be based on chance.
We hypothesised that we would find considerable intra-individual differences in blood pressure 
response to both study drugs, but that the mean blood pressure reduction of valsartan and 
hydrochlorothiazide would be the same. However, in our study sample valsartan was slightly 
more effective in reducing blood pressure then hydrochlorothiazide. 
In an attempt to understand this difference, results from post-hoc analysis suggested that 
plasma renin concentration does not affect response to valsartan; that part of the difference 
depends on sex and that valsartan is equally effective in patients younger than 55 compared to 
those of 55 years and older. 
Rather than valsartan to be less effective in older patients it is hydrochlorothiazide that seems 
to be less effective in younger patients. This conclusion is in agreement with one study that 
demonstrated that treatment success for diastolic blood pressure (data of systolic blood 
pressure were not presented) of captopril was similar in young and old white patients (cut-off 60 
years) and that in old whites treatment response of captopril was similar to hydrochlorothiazide. 
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Only in young whites hydrochlorothiazide appeared to be less effective.11 However when 
scrutinizing the source of the data of this study 24, systolic blood pressure response to captopril 
and hydrochlorothiazide in white patients did not differ between age groups for each medication 
nor between both medications.
Since 2006 the NICE/BHS guideline recommends to stratify treatment in uncomplicated 
essential hypertension based on race and age. 9;32 In patients younger than 55 years, treatment 
should start with an ACE inhibitor or ARB whereas in patients of 55 years and older CCB’s 
should be the first choice medication (AB/CD rule). The NICE recommendation is based on the 
pathophysiological assumption that at least part of the patients with uncomplicated essential 
hypertension can be divided in low renin (salt sensitive) and high renin (vasoconstrictive) 
hypertension.18;33 This concept combined with the finding that plasma renin activity declines 
with age was used as the foundation of the modified Cambridge AB/CD rule.9;18;32 In this rule age 
and race are regarded as surrogates for plasma renin and as such as predictors of treatment 
response. Unfortunately, a prospective study proving the cost-effectiveness of the AB/CD rule 
is lacking. Meanwhile, with regard to age and renin the results of our study do not support the 
theoretical frame work used to formulate the AB/CD rule. Data from two crossover trials 3;4 and 
one randomised controlled trial 24 constitute the core evidence for the Cambridge rule. However, 
as pointed out in the introduction these studies have several limitations. More importantly, if age 
and renin are indeed key elements in predicting treatment response how can it be explained 
that in all studies, including the current one age and renin were never convincingly found to be 
predictive?
One answer might be that in the age range when hypertension is diagnosed most frequently, 
the pathofysiological mechanism of the development of essential of hypertension is a mixed 
bag were the model of high versus low renin hypertension only applies to a very small minority.
Our results do show that in some individuals differences in blood pressure response are very 
large, most likely due to a predominant mechanism. Unfortunately, our study suggests that it 
is not possible to tell beforehand what the predominant mechanism is in an individual patient.
Strengths and limitations
Although our study findings can be generalised to everyday general practice with newly 
diagnosed patients in the age range when diagnosis of (essential) hypertension is most 
common, there are several limitations.
We included a rather homogenous group of patients in a relevant age range larger than previous 
crossover studies. However, lack of sufficient elderly patients (older than 65 years) may have 
contributed to the fact that we could not identify age as predictor of blood pressure response. 
Low and high renin hypertension are likely to be present more frequently in the extremes of the 
age distribution but less so in the age range when hypertension is diagnosed most. 
The objective of our study was not to study the efficacy of the studied drugs. In such studies 
usually a protocol with intention to treat analysis is preferred. We used a per protocol analysis 
in those patients with full data at least including the second treatment period. It is unlikely that 
intention to treat analysis with the 22 patients lost to follow up would alter our conclusions. 
Not only were these patients in baseline characteristics similar to the study sample, more 
importantly already seven of them stopped before the first treatment either because of human 
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error in study protocol or because patients disliked 24hr ABPM at run in. 
Assessment of urinary sodium excretion 10;11;33 would have enabled improved subtyping of 
patients in different sorts of essential hypertension as opposed to our pragmatic approach 
with tertiles of plasma renin concentration. However, we decided not to study sodium excretion 
because of its patient unfriendliness and erratic results it is unlikely that this variable is easily 
implemented in general practice. We aimed to use equipotent doses of both studied drugs 29, 
but a minor difference in equipotence may explain the mean difference in response between 
valsartan and hydrochlorothiazide. 
Considerations for future research
In the search for improved hypertension control, more research on the identification of predictors 
of blood pressure response in an attempt to enable personalised hypertension management 
probably will have very limited value. Our results do not support a role for age as surrogate for 
plasma renin and for renin as predictor itself. Prospective clinical trials evaluating the use of the 
AB/CD rule versus the management protocol of the ESH guideline and studies evaluating renin 
driven initiation of treatment versus usual care could help end the ongoing controversy with 
regard to this topic. If such trials prove to be inconclusive or even reject a useful role for renin 
or age in the initiation of treatment than the improvement of hypertension control needs better 
alternatives than patient tailored strategies. 
Conclusion
We did not find predictors that support a personalized hypertension treatment strategy in 
uncomplicated essential hypertension. We did find large intra individual differences in treatment 
response which in our view justifies initiation of mono therapy and switch to another mono 
therapy when the first proved to be unsuccessful. The choice of the first drug should be based 
on costs, anticipated adverse events, co-morbidity and patient opinion.
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Table 1. Baseline characteristics (SD) for patients who completed both medication periods 
compared to the subgroup of patients lost to follow up  
DayABPM = daytime ambulatory blood pressure measurement; 
SBP = systolic blood pressure; 
DBP = diastolic blood pressure; 
OBPM = office blood pressure measurement; 
BNP = brain natriuretic peptide; 
eGFR = estimated Glomerulal Filtration Rate; 
MDRD = modification of diet in renal disease; a n=89 ; b n=14
97
patient tailored treatment of hypertension
Table 2. Univariate linear regression analyses with systolic blood pressure response to 
hydrochlorothiazide as dependent variable  
BMI = body mass index; 
BNP = brain natriuretic peptide; 
eGFR = estimated Glomerulal Filtration Rate; 
MDRD = modification of diet in renal disease. 
We used p=0.05 as cut off for inclusion of variables in the next step of the model; 
waistcircumference excluded from model because of collinearity with BMI
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Table 3. Univariate and multiple linear regression analyses (manual forward selection procedure) 
with systolic blood pressure response to valsartan as dependent variable
Table 4. Effect size of mean systolic blood pressure reduction by hydrochlorothiazide (HCT) 
and valsartan for subgroups based on age, sex and plasma renin tertiles
BMI = body mass index; 
BNP = brain natriuretic peptide; 
eGFR = estimated Glomerulal Filtration Rate; 
MDRD = modification of diet in renal disease. 
We used p=0.05 as cut off for inclusion of variables in the next step of the model; 
waistcircumference excluded from model because of collinearity with BMI
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Figure 1. Study design and time course of mean daytime ambulatory systolic blood pressures 
Error bars represent standard error of the mean
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Figure 2. Patient flow and loss to follow up
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Figure 3. Intra-individual systolic blood pressure response to both study medications
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In essence
This thesis dealt with two topics, both with the objective to improve hypertension management 
in primary care.
First, we clinically validated a novel approach of office blood pressure measurement (OBPM) to 
minimize measurement bias and to overcome the white coat effect: 30 minute serial, automated 
office blood pressure (30-min AOBPM). In three different sets of patients we demonstrated 
that sitting 30-min AOBPM readings are lower than readings with standardized OBPM; that 
the reproducibility of 30-min AOBPM is better than standardized OBPM and that both sitting 
and supine 30-min AOBP agreed well with daytime ambulatory blood pressure measurement 
(ABPM). This first phase of validation justifies exploration of the implementation of 30-min 
AOBPM in usual care.
Second, in a representative sample of newly diagnosed hypertensive patients in primary care we 
searched for predictors of the response to either a diuretic or an angiotensin receptor blocker. 
If predictors exist, these could tailor treatment to the individual patient and as such increase the 
efficient use of medication and resources. Although we found large intra-individual differences 
in treatment response to both studied drugs, we were unable to identify such predictors. 
30-min AOBPM
Methodological considerations
We would like to highlight two aspects of 30-min AOBPM that warrant discussion: 
• The influence of the (clinical) setting of blood pressure measurement on the white coat 
effect
• The duration of AOBPM
The first issue has a direct link with the perceived mechanism of white coat effect. While it has 
been described that within a clinical setting this effect is mainly attributable to the observer 
taking the blood pressure1;2, the question remains whether –independent of the presence of the 
observer- the clinical setting itself also contributes to the white coat effect and if this contribution 
is clinically relevant. If the clinical setting itself plays a substantial role in the development of 
white coat effect, than 30-min OBPM would lose part of its appeal. 
Unfortunately, research on the etiology of white coat effect is scarce and its mechanism remains 
poorly understood. Until now patient-related psychological effects are regarded to be the most 
important contributor to the white coat effect. Research demonstrating blood pressure to be 
higher when taken by a senior compared to a junior doctor or between doctor and nurse 
supports this3;4, as well as research suggesting that patient’s perception of being hypertensive 
contributes to the development of white coat effect.5 It is theorized that part of the patients 
will either conscious or subconsciously associate the doctor and her office with pain, sorrow, 
miscommunication or unfavorable medical treatment with an anxious state including a rise in 
blood pressure as a consequence.2 Also, anticipation  or curiosity about the blood pressure to 
be measured could be of relevance.
To our knowledge only one study provides some data about the contribution of setting (both 
non-clinical and clinical) versus the role of the doctor in the development of the white coat 
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effect.1 Results from this study showed that anxiety increased going from the non-clinical 
environment to the waiting room of the clinic.  Blood pressures were higher in the waiting 
room than in the non-clinical setting for all four subgroups (sustained, white coat, masked, 
normotension) of hypertension. This difference in blood pressure was considerably smaller than 
that introduced by the presence of the doctor. The main conclusion was that the conditioned 
response to a doctor taking the blood pressure was the most powerful influence on the patient’s 
blood pressure. Although we did not formally study the effect of setting on the results of 30-
min AOBPM, based on the above-mentioned research1 and based on our findings that 30-min 
AOBPM agreed well with the measurements taken outside the clinic using ABPM we conclude 
that 30-min AOBPM is able to quantify most if not all of the white coat effect.
 
Even though 30-min AOBPM takes considerably less time than 24-hour ABPM or HBPM, office 
management clearly benefits from even shorter interventions; it simply serves more patients 
per day. Results of the research group of Myers using the purpose built BpTRU blood pressure 
measurement device for their AOBPM suggest that measurement times of as little as 5-10 
minutes (with a 1 minute measurement interval) give reliable results.6 We chose to start with 
30 minute measurement duration for a theoretical and a pragmatic reason. First we based 
our measurement time on data from several studies suggesting that in a time course of blood 
pressure measurements blood pressure does not reach a plateau phase within the first 10 
minutes.7-9 Results as presented in this thesis underline this assumption. Second, we used a 
24-hour ABPM device with –at the time of the research- a minimum measurement interval of 5 
minutes. To facilitate a mean of at least 5 measurements we needed a measurement time of 
thirty minutes.
Myers demonstrated similar agreement between his protocol of 5 to 10 minutes of measurement 
and daytime ABPM. However, scrutinizing the previous work of Myers showed that in those 
studies with data available on the comparison of AOBPM with daytime ABPM the standard 
deviation of the difference (SDD) proved to be around 15mmHg10-12 while in our studies the SDD 
was around 9 mmHg, which is similar to SDD’s as reported in 24-hour ABPM reproducibility 
studies.13-16 This implies that agreement between 5-10 minute AOBPM and daytime ABPM is 
inferior to that between 30-min AOBPM and daytime ABPM, involving differences more than 
can be explained by biological variation alone. This poorer agreement could be a consequence 
of error caused by blood pressure not yet reaching its plateau phase combined with the fact 
that the protocol of Myers calculates a mean blood pressure based on five measurements 
compared to six in 30-min AOBPM.  To obtain optimal results we therefore conclude that a 
measurement period of 30 minutes and a minimum of five measurements are to be preferred.
Future research
Evaluation of the perception of patients and health care staff about the use, feasibility and 
patient friendliness of 30-min AOBPM compared to HBPM and daytime ABPM could further 
support the implementation in daily practice. Moreover, it would help acceptance of AOBPM 
if we can further elucidate the mechanism of white coat effect and confirm that clinical setting 
itself only contributes modestly (if not at all) to this phenomenon. Next, in a clinical trial, use 
of 30-min AOBPM in the diagnostic workup of patients with elevated blood pressures should 
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provide evidence for its cost-effectiveness. The question whether early advanced diagnostic 
workup indeed reduces the number of “diagnostic visits” to the general practices before a 
doctor confirms the diagnosis hypertension could be answered in such a trial, just as it will 
enable insight in the number of patients “saved” from an unjust diagnosis of hypertension and 
unjust initiation of medication. Finally, it will tell whether this reduction in unnecessary diagnosis 
and treatment balances the investment in the use of 30-min AOBPM. 
Clinical implications and future prospects
Unfortunately results of serial AOBPM cannot be used directly in cardiovascular risk functions 
like the one based on the Framingham study or the European SCORE risk function.17;18 After 
all, these functions are based on data derived from standardized office measurements. This 
disadvantage is not unique for serial AOBPM but also hampers applicability of ABPM and 
HBPM and can be partly overcome in a similar way to the interpretation of additional risk 
factors that are not part of the risk function (like family history, obesity, sedentary life, etc). While 
guidelines encourage physicians to take these additional risk factors into account by increasing 
the calculated risk with an estimated guess19;20, a diagnosis of relevant white coat effect could 
be used as argument to reduce this risk.
The successful first steps of validation of 30-min AOBPM as novel approach in office blood 
pressure management, in combination with the available data of other research groups working 
on AOBPM has stimulated us to formulate how 30-min AOBPM may fit in current hypertension 
diagnostic work up. The proposed flow of diagnostic evaluation is depicted in figure 1. This 
proposition needs to be validated by data as described earlier in “Future research”.
As shown in this figure it is at the discretion of the doctor and the patient what type of additional 
blood pressure measurement (HBPM, ABPM or 30-min AOBPM) is preferred. If information on 
true blood pressure status suffices than the choice will depend on patient’s preference and 
abilities, available type of blood pressure measurement devices and local setting. If additional 
information like night time blood pressure or dipping status is required than the choice will be 
limited to ABPM. If only information on true blood pressure status is needed our preference 
lies with the use of 30-min AOBPM. Compared to HBPM and daytime ABPM this type of 
measurement is the most standardized type of measurement, which is a major advantage in 
the interpretation of follow up measurements.    
For the near future we foresee a further increase in the use of HBPM and 24-hour ABPM. 
The very recent publication of the new version of the Dutch multidisciplinary guideline on 
Cardiovascular risk management has introduced extensive sections with regard to indication, 
use/implementation and interpretation of these types of measurements, which will stimulate 
evidence based application of these type of measurements.20 
The recent publication of the British NICE guideline on hypertension management has gone 
even one step further and now recommends that for the purpose of identification of white coat 
effect 24-hour ABPM or HBPM should be in the standard work up of each patient with elevated 
office blood pressures.21 The evidence base for this recommendation is subject to heated 
debate.22 In contrast to the current NICE guideline we think doctors should be allowed OBPM 
follow up without 24-hour ABPM, HBPM or 30-min AOPBM in case elevated blood pressure is 
perceived to be a consequence of a temporarily stressful period in a patient’s life.
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NAMI study
Methodological considerations
The results of the NAMI study form a small weight that will probably not tip the scale and end 
the controversy about the use of predictors in hypertension management. Although the body 
of knowledge that has accumulated over the last decades appears to be quite substantial, a 
systematic evaluation of the type of knowledge may help to understand why the controversy 
remains. For this systematic evaluation we first formulated the methodological / epidemiological 
requirements needed to draw firm conclusions about the predictive qualities of a studied 
variable (Box 1).
Step 1: Theory for predictors
Although not without debate, this first step seems to be fulfilled with the model based on RAAS 
as described in the Introduction chapter of this thesis. However, the complex regulation of blood 
pressure involves more than RAAS and entails a variety of organ systems (central nervous 
system, cardiovascular system, kidneys and adrenal glands) and regulatory mechanisms that 
are all intricately linked. 
Multiple types of feedback loops with both acute and chronic adaptation to different 
haemodynamic states add to the complexity.23;24 It is not unreasonable to assume that the 
proposed model is too much of a simplification, which then may lead to inconclusive evidence. 
In addition, according to the model, low renin patients should have excessive extracellular and 
plasma volume and although several studies have demonstrated this relationship 25;26, several 
others did not.27-29
What may be interfering with the robustness of all suggested models is the fact that patients 
with essential hypertension are a very heterogeneous group. This heterogeneity may be of 
such an extent that it will limit the possibility to predict response to treatment.28;30
Step 2: Valid method of measurement
To validate the renin model a reliable assay to determine plasma renin is essential and 
preferably there should be one international standard. Unfortunately, an international standard 
is lacking and both assays determining plasma renin activity and plasma renin concentration 
Box 1. Requirements for a variable to be a convincing predictor
1. A theory (mechanistic, etiologic, pathophysiologic, etc) why a variable could have 
predictive power
2. A valid method of measurement of the variable
3. Prospective study in relevant population that demonstrates an association between 
variable and outcome 
4. Verification of this finding in additional patient cohorts
5. Randomised clinical trials demonstrating that predictor based treatment is more 
cost-effective than usual care
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are used. As pointed out previously until recently the quality and interpretation of plasma renin 
activity assays was subject of debate.29;31 In summary, although current assays seem to fulfil 
the conditions of this second step, a substantial part of the previous work on predictors was a 
source of controversy due to less reliable renin assays. 
 
Step 3 & 4: Prospective data demonstrating association between predictor and outcome
With doubts about meeting the conditions of step 1 and 2 it is not surprising that prospective data 
on potential predictors were conflicting (table 1, Introduction). In addition, the methodological 
limitations with regard to study design, sample size, sex distribution and patient selection 
further restrain interpretation of results. The NAMI study was set up in an attempt to overcome 
these obstacles. 
Step 5: RCT demonstrating cost effectiveness of predictor based treatment  
To our knowledge only one proof of concept study has compared a predictor (plasma renin) 
guided treatment algorithm with usual care.32 The sample was small with only 57 patients, 
patient selection included treated, but uncontrolled patients selected from hypertension clinics 
and costs were not studied. Taking the uncertainties as described in the first four steps into 
account, it is not surprising that fundibg this final 5th step has been a challenge and that until 
now this research is missing. A recent comment on controversies in hypertension management 
suggests that the 5th step is underway.33  
Clinical implications
Despite the controversial evidence base for the use of predictors in hypertension management 
and in contrast with the European and American guidelines 17;35, the British NICE guideline 
on hypertension management recommends the use of an AB/CD treatment algorithm. In this 
algorithm “A” stands for ACEi, “B” for ß blocker, “C” for CCB and “D” for diuretic. Age –regarded 
as surrogate for renin- is used at a cut off of 55 years: in younger patients ACE (or ß blocker) 
should be started, in older patients CCB (or diuretic).21 The recent Dutch multidisciplinary 
guideline on cardiovascular risk management has followed this recommendation with the minor 
adjustment to use a cut off of 50 years.20 The rationale for this algorithm was based on the 
interpretation of a selection of evidence in four steps.21;36 
1. Studies demonstrating the inverse relation between plasma renin activity and age.37 
2. Crossover trials demonstrating intra-individual differences in treatment response.38;39 
3. Crossover trials and one RCT suggesting that in young patients ACEi and ß blockers work 
better, in older patients CCB and diuretics.38-40
4. Primary and posthoc analyses of large RCT’s on the efficacy of antihypertensive medication 
demonstrating that CCB and diuretic are more effective in older patients.41-44
After scrutinizing the studies that were used to come to the NICE recommendation we do not 
share the conclusions put forward in the last two steps. While the crossover trials referred to in 
step 3 did not include patients older than 55 years and included less than 50 patients, data from 
the RCT clearly show that systolic blood pressure reductions for old and young white patients 
(similar to the NAMI population) for both diuretic and ACEi were similar.
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The conclusion in step 4 was undermined by a recent meta-analysis which concluded that both 
blood pressure reductions and cardiovascular event rates are similar in old and young patients 
for the different drug classes.45 In addition, also the results from the NAMI study do not support 
this theoretical framework. We therefore advocate physician driven best estimated guess for 
first choice treatment taking patient’s context, co-morbidity, preferences and costs into account. 
Future research
From a purely scientific point of view and based on the current evidence it seems reasonable to 
conclude that predicting response to different classes of antihypertensive treatment in patients 
with essential hypertension is not possible and that further research exploring this topic is of 
little use without new knowledge with regard to the first two steps of Box 1.
From a pragmatic point of view it could be worthwhile to end the controversy about the use 
of predictors by setting up a methodologically sound RCT to explore whether renin driven 
initiation of treatment is a cost effective approach of hypertension management.  
Research on how to improve hypertension control should focus on ways to improve treatment 
adherence of both doctors and patients. Telemedicine/e-medicine to stimulate patient self 
management 34 and expert systems integrated in the electronic medical file of physicians 
could be useful interventions to improve hypertension control. Moreover, research is needed to 
evaluate whether instant initiation of combination treatment outweighs trial and error initiation 
of different classes of mono therapy.  
Final remarks
Both research topics in this thesis dealt with hypertension which, as an important risk factor, is 
part of cardiovascular risk management. This type of management is aimed at prevention of the 
first event or the recurrence of cardiovascular disease. 
Prevention has gained increasing attention by policymakers as part of the solution to deal with 
the deficit between available resources in health care and the expected progressive increase in 
demand. While prevention and public health have a lot to offer, the current focus on prevention 
may have the undesirable side effect of fuelling the perception of people that perfect health is 
in one’s own hand 46, even to an extent where suffering a myocardial infarction despite a low 
cardiovascular risk is still regarded as one’s own fault.47 In addition some preventive measures 
will inevitably lead to over diagnosis and over treatment.48
As a general practitioner I am worried that our profession is about to lose what I believe to be 
a powerful asset: the art of parsimony. Several factors contribute to this development of which 
the focus on prevention is only one. In the final part of this thesis together with several others 
I have addressed this concern. It explores how less can be more and how physicians need to 
stand for their ability to wisely do less.  
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Figure 1. Proposed work up of patient with elevated office blood pressure
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The art of parsimony
Medicine is about to lose a powerful asset that has become difficult to put into practice: the art 
of parsimony. Previously described as watchful waiting or quaternary prevention 1, it stands for 
an active role for the doctor to reach an agreed upon alternative for an initial patient’s wish for 
diagnostic workup or medical treatment, which from a medical viewpoint seems unnecessary 
or harmful.2 
Here we describe why this art is important for medicine, what is needed to practice it, the threats 
to practising it, and our suggestions how to maintain it.
Why is it important?
Parsimony makes sense simply because it is efficient; producing better health for fewer 
healthcare costs.3 Case reports 4, primary research 5, and overviews 6;7 have demonstrated 
the harm of overutilization of diagnostic tests and treatment. Harm can be caused by adverse 
events but also by negative socio-psychological consequences of (falsely) labelling disease.8
If practiced well the art of parsimony will strengthen the patient-doctor relationship (by requiring 
the doctor to better understand and manage the patient’s expectations) 9 and thereby enhance 
quality of care and satisfaction, of both patient and doctor.
Of course parsimony is not a goal in itself. Not only will it then increase missed diagnoses 
and undertreatment, it would also risk raising the suspicion of our patients that we are more 
interested in saving money than caring for them. Rather parsimony aims to protect our patients 
from harm or overuse, promote self-reliance in health, and judiciously use available resources.
What is needed?
A prerequisite to be parsimonious is the doctor’s ability to combine medical expertise and 
excellent communication skills with self-knowledge and a holistic view of the patient. This will 
enable building a patient-doctor relationship based on trust.10;11 Doctors are then set to predict 
the added value of interventions against the natural course of the health problem, to weigh 
the patient’s perspective, to judge the time frame for eventual reassessment, and to identify 
indicators against which to (re)assess.11
Threats to medical parsimony: societal and medical changes
The medical profession has itself contributed substantially to lack of parsimony. Doctors have 
contributed to ‘medicalisation’ of once-normal aspects of the human condition. Patients can 
now be pre-hypertensive 12, and are no longer sad but are suffering from ‘moderately severe 
depression’ requiring drug treatment and psychological intervention.13
Another contributing factor is the notion of ‘anti-litigation practice’, the ordering of tests or 
offering treatments not so much to benefit patients as to protect doctors. Medico-legal criticism 
of individual cases tend to focus more on underuse (failing to test or treat) than overuse, 
(especially in prevention), perhaps reflecting the difficulty we have in practising medical 
parsimony.
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Also the constant pressure on time experienced by most doctors will hamper parsimony. This 
stimulates ordering futile diagnostics, because it is quicker to offer overmanagement than to 
explain why not. For all these reasons doctors have “trained” their patients in the desire for 
more instead of fewer interventions.
Society itself has changed in several ways. People (including doctors) have become hyper-
vigilant to risks in life and appear to have increasing difficulty to deal with uncertainty.14 Values 
like individual autonomy and personal freedom have become important and coincide with a 
decrease in ‘social capital’ consequent on our being less religious and less part of tight-knit 
social networks.15 ‘God’s will’ or ‘destiny’ is replaced by a demand for medicine to eliminate 
uncertainty and fix illness or distress. Patients increasingly expect this fixing to be done 
immediately, perfectly, and with minimal effort from themselves. 
The organisation of health care has changed from one primarily based on the value of solidarity, 
to a market orientated organization, increasingly based on individual responsibility.16 This 
change supports the role of patients as consumers of health care, rather than ‘responsible 
for one’s own health’ in a sensible way. The conjoint restructuring of health care finance has 
introduced incentives for doctors to perform diagnostic workup and start treatment (pay for 
performance). Unfortunately, this will rather support over- than underuse of medical services.
Next to our intuitive affinity with trust as an important contributing factor to parsimony, research 
has clearly demonstrated the quality of care and cost effectiveness of high trust patient-doctor 
relationships.11;17;18 Ironically, despite this evidence the societal, political and even medical world 
appears to be navigating away from it.19;20 Medical misconduct and increased media exposure 
have contributed substantially to this process. 
Furthermore, medical information is now available to the public through a variety of sources 
(friends, media, virtual communities, wiki’s, government, doctors, etc) with –through its 
multitude– a considerable chance of being conflicting.21 Data from the swine flu (H1N1) epidemic 
have shown that conflicting information was the major cause of the significant decrease in 
confidence in the Dutch government during the progress of the epidemic.22
This decline in confidence has induced a steady increase of measures of accountability that 
seem to evolve in a direction where confidence is replaced by protocol.20 We foresee these 
developments to also negatively influence trust on the level of the individual patient-doctor 
relationship. Bensing and co-authors recently demonstrated that in 15 years time consultations 
have indeed become more protocolised, without an increase in shared decision making.23 
Other factors that influence the role of trust in the patient-doctor relationship have to do with the 
changed image of doctors in society. From a “magician”, part of an elite minority with exclusive 
knowledge on health and disease, he has changed into a peer, a person who “merely” executes 
protocols and guidelines which are readily available to the public with the use of internet. He 
has become part of, and is dependent on, a team of health care workers, and for a growing 
number of patients is trained at a similar, academic level. 
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A priori trust has therefore decreased and trust has more than ever to be earned just like in 
any other interpersonal relationship. The above-mentioned threats are strongly interrelated and 
seem to feed each other in a synergistic way, which has now put more pressure on parsimonious 
medicine than ever before.
Suggestions how to maintain the art of parsimonious medicine
The factors outside our control (related to societal perception) need something outside our 
profession. However as doctors there are things we can do:
•	 Take a stand against moves towards a market-driven health industry; instead we should 
focus on maintaining and enhancing the patient-doctor relationship. Experiments are 
needed to find payment methods that promote prudent use of resources.
•	 Invest not only in our own quality of care, but in that of our colleagues as well. Trust 
increasingly depends on the patient-health care team relationship, and we need to better 
understand how this can happen. Together with Stange we foresee that continuous 
personal connections remain of utmost importance.11
•	 Use of social media and internet based networking, to communicate better with younger 
generations.15;24 This may seem somewhat ironic given the fact that new media also feed 
patients with all kinds of incorrect information, which can cause distress and medical 
consumerism. However, using these types of media to communicate, facilitate the process 
of care and create or direct to reliable evidence-based sources of medical information may 
help counteract this.21 More research is needed to inform this process.
•	 Medico-legal reform. Doctors have to develop forms of intelligent accountability that 
enable them to work in the best interest of patients without the fear of unfair penalty if an 
error is made unintentionally and in good faith.10 This has to be seen as scrupulously fair, 
and probably should be governed external to professional control, to gain the trust of the 
community.
•	 Medical parsimony should be part of every doctor’s critical thinking. This will require 
continuous education by strong role models from the beginning of medical training 
onwards.
•	 Performance indicators are almost exclusive directed at what doctors do, not at what they 
do not do.25 However, they should also reflect parsimony. Comparisons between clinics 
or hospitals can identify overuse of diagnostic and treatment options. Doctors seem to be 
willing to reduce overuse by learning from comparison with colleagues on efficient use of 
resources.26
Policy makers face the challenge of dealing with a continuous growth of health care demand 
with a paucity of well-trained medical staff and limited financial resources. Part of this growth 
can be explained by excessive use of resources. Counter intuitive as it may be, to stop the 
growth of medical overutilization, more than anything else, investments in an optimal patient-
doctor relationship are needed. Only then the art of parsimony can be practised.
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Box 1. Medical Parsimony: Problems and Solutions
1. Doctors create disease and practice defensive medicine; Continuous education of 
students and doctors about harm by overuse. Reconsider the position in guideline 
committees of medical opinion leaders tied to pharmaceutical companies. Doctors 
and patients together need to be actively involved in the creation of intelligent 
accountability.
2. Increased difficulty to deal with uncertainty; Doctors have to be authentic and 
consistent in their information and management. Doctors should be well trained in 
risk communication.
3. The societal claim for perfect health; Guidelines need to clearly state the boundaries 
of where evidence ends and wisdom begins and if possible include numbers needed 
to treat and harm. Doctors have to invest time to explain patients the limitations of 
medicine and the chances on harm from testing or treatment; this will only work in 
relations with trust.
4. A market driven organization of health care; Restrict pay for performance to evaluated 
care. Create incentives for doctors and health care teams that demonstrate high 
quality of care with low consumption.
5. Inability to built trust between patient and doctor; Research whether trust in health 
care teams is as effective as trust in individual doctors. Evaluate the use of social 
media and internet networking to built trust in modern ways. Building trust takes 
time; prevent downsizing of actual consultation time.
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Summary
This thesis addressed the suboptimal control of hypertension, focussing on a new type of 
office measurement that could improve diagnosis of hypertension and on the use of predictors 
of treatment response to different classes of antihypertensive medications.
In Chapter 1 the rationale and objectives of this thesis are described. Even though multiple 
effective and affordable medications to treat hypertension exists and the relevance of adequate 
treatment is without debate hypertension control remains suboptimal. Guidelines were 
developed to help general practitioners to improve this suboptimal control. However, it is unclear 
if the content of these guidelines actually is translated to changes in daily general practice. 
In this thesis we describe our study of two different strategies to improve hypertension control. 
First of all we studied a new type of office blood pressure measurement (OBPM). OBPM is 
subject to different types of measurement error and often overestimate true blood pressure 
status. Blood pressure measurements outside the office using 24-hour ambulatory blood 
pressure measurement (24-hour ABPM, automated measurements at regular intervals with 
device coupled to patient) or home blood pressure measurement (HBPM, protocol guided self 
measurement at home) are more reliable than OBPM but both come with several disadvantages. 
Second, we studied whether personalised medicine could be used in the treatment of newly 
diagnosed hypertensive patients without cardiovascular co-morbidity. So far data on this 
subject were inconclusive. While some results suggested that patient characteristics like age, 
sex and plasma renin predict the response to different classes of antihypertensive medication, 
others do not. In our view, several, relevant methodological and epidemiological limitations of 
these previous studies exist. 
In chapter 2 we describe results of a descriptive study on the impact of the Dutch guideline 
on hypertension management and two subsequent revisions on the process and outcome of 
hypertension management in general practice. Three cohorts of patients were defined, each 
managed during a period with a different version of the guideline available. The mean age of 
patients in these cohorts rose from 55 years (1992-1996) to 60 years (2004-2006). Mean blood 
pressure at initiation of treatment remained similar (175-179/99-106 mmHg). 
The objectives of these thesis were:
1. To study the impact of guideline revisions on the process and outcome of hypertension 
management in primary care
2. To validate the concept of a 30 minute serial automated office blood pressure 
measurement (AOPBM) in a primary care population using an ambulatory blood 
pressure measurement device. 
3. To identify patient characteristics that predict blood pressure response to two classes 
of antihypertensive drugs, each interfering with a different pathophysiological 
pathway of hypertension. 
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The relative two year systolic and diastolic blood pressure decline (13.3 – 15.7% systolic) 
differed only modestly between cohorts. Mean two year follow up blood pressure ranged from 
148-151/85-89 mmHg. The percentage of patients with three or more antihypertensive drugs 
remained equal (22-23%). In agreement with revisions in the guidelines, the use of diuretics 
as first-choice drugs increased significantly from the first to the last cohort. We concluded that 
general practitioners achieve substantial and prolonged blood pressure reduction. However, 
guideline revisions do not seem to influence the amount of reduction, despite clear formulation 
of stricter treatment goals.
Chapter 3 presents data of a method comparison study between blood pressure measured with 
sitting 30-minute AOBPM compared to standardised OBPM and data on the reproducibility of 
30-minute AOBPM. Mean 30-minute AOBPM readings were 8/3 mmHg lower than standardized 
OBPM readings. The mean difference and standard deviation of the difference (SDD) between 
repeated 30-minute AOBPMs (mean difference = 3/1mmHg, 95% CI = 1 to 5/0 to 2mmHg; 
SDD 10/5 mmHg) were lower than those of standardised OBPM (mean difference = 6/2mmHg, 
95% CI = 4 to 8/1 to 4mmHg; SDD 11/6 mmHg). In conclusion, these results suggested that 
30-minute AOBPM better reflects true blood pressure status than standardised OBPM and with 
better reproducibility.
 
Next, in chapter 4 we describe our study of the agreement between sitting 30-minute AOBPM 
and daytime ABPM. Mean systolic and diastolic blood pressures differed 0 to 2 mm Hg 
respectively (with limits of agreement between between -19 and 19 mm Hg for systolic and -10 
and 13 mm Hg for diastolic blood pressures) between 30-minute AOBPM and daytime ABPM. 
Both 30-minute AOBPM and daytime ABPM classified normotension, whitecoat hypertension, 
masked hypertension, and sustained hypertension equally. We concluded that 30-minute 
AOBPM agreed well with daytime ABPM and had the potential to detect white-coat and masked 
hypertension. 
Chapter 5 reports on a similar study as described in chapter 4 but in a different set of patients 
and now with a comparison of supine 30-minute AOBPM and daytime ABPM.  Systolic blood 
pressure differed -1 (-4 to 2), 17 (14 to 20) and 2 (-1 to 4) mmHg between supine 30-minute 
AOBPM and daytime, nighttime and 24-hour ABPM respectively (95% CI of error). Supine 
30-minute AOBPM classified normotension; white coat hypertension; masked hypertension and 
sustained hypertension equal to daytime ABPM. We concluded that similar to sitting also supine 
30-min AOBPM agreed well with daytime ABPM, but that we prefer a sitting measurement.
Chapter 6 describes the results of the NAMI study, a crossover design to identify patient 
characteristics that could predict the response to either a diuretic or angiotensin receptor blocker. 
We studied age, sex, menopausal state, plasma renin concentration, NT-proBNP, potassium, 
estimated glomeral filtration rate, urinary albumin, body mass index and waist circumference as 
potential predictors and used daytime ABPM as main outcome measure for the blood pressure 
response. Besides BMI -which was significantly related to the effect of valsartan (ß -0.63, p 
= 0.04) - the studied variables were not predictive for blood pressure response. Individual 
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systolic blood pressure responses ranged from an increase by 18 mmHg to a decrease of 
39 mmHg. In conclusion, we did not find clinical relevant predictors that could substantiate 
personalised hypertension treatment in uncomplicated essential hypertension. This conclusion 
does not support the British NICE hypertension guideline  treatment algorithm were age is used 
as predictor for treatment response.
In chapter 7 we discuss the main findings of this thesis, address several methodological issues 
and point out clinical implications and future research. 
With regard to 30-minute AOBPM we concluded that the first steps of validation were successful 
and that for assessment of true blood pressure status this type of measurement can be used 
in daily practice. To substantiate implementation in daily practice study on the perception 
of patients and health care staff about the use, feasibility and patient friendliness of 30-min 
AOBPM compared to HBPM and daytime ABPM is needed. In addition, a clinical trial is required 
to study whether use of 30-min AOBPM in the diagnostic workup of patients with elevated blood 
pressures is indeed cost-effective.
Results of our crossover study to identify potential predictors of the efficacy of antihypertensive 
medication points out that personalised medicine in patients with essential hypertension but 
without cardiovascular co-morbidity with the current knowledge is unlikely to be successful. 
In a systematic approach we have formulated what is needed for a potential predictor to be 
recognised as such and did we try to unravel what has caused the current contradictory results 
in research on predictors in hypertension treatment. 
With our current knowledge we conclude that predicting response to different classes of 
antihypertensive treatment in patients with essential hypertension is not possible and that 
further research exploring this topic is of little use. 
We therefore advocate physician driven best estimated guess for first choice treatment taking 
patient’s context, co-morbidity, preferences and costs into account. Research to demonstrate 
whether searching for the best fit mono therapy versus direct start with combination treatment 
is needed.           
 
We end this thesis with an Epilogue that puts the results of this thesis in the perspective of 
changes in society and the medical profession. Our research tried to contribute to reduction 
of overdiagnoses and overtreatment of hypertension. However, we have noticed that medico-
legal changes, pay for performance in health care, focus on prevention, societal perception on 
health, autonomy and risk seems to put pressure on doctors to overdiagnose and overtreat 
rather than vice versa. In our essay we propose a change for the better.
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Samenvatting
Dit proefschrift behandelt onderzoek dat kan bijdragen aan het verbeteren van de zorg voor 
patiënten met een hoge bloeddruk. We rapporteren over  een nieuwe manier van bloeddruk 
meten in de huisartspraktijk die de diagnostiek van hypertensie kan verbeteren. Daarnaast 
beschrijven we of er patiëntkenmerken bestaan die de respons op twee verschillend werkende 
bloeddrukverlagende medicijnen kunnen voorspellen. Hiermee zou de behandeling van hoge 
bloeddruk aanmerkelijk geoptimaliseerd kunnen worden.
In Hoofdstuk 1 geven we een onderbouwing voor de geformuleerde doelen en de verrichte 
onderzoeken zoals beschreven in dit proefschrift. Het is uitvoerig bekend dat een aanzienlijk 
deel van de mensen met hypertensie onvoldoende behandeld wordt. Er zijn richtlijnen over 
hypertensie opgesteld onder meer om deze onderbehandeling te voorkomen. Het is echter niet 
duidelijk wat de invloed van deze richtlijnen op het handelen van huisartsen is. 
Bij het meten van de bloeddruk in de huisartspraktijk is door verschillende soorten van 
meetfouten vaak sprake van overdiagnostiek van hypertensie. Een 24-uurs bloeddrukmeting, 
waarbij een meter die de patiënt permanent bij zich draagt twee tot vier keer per uur automatisch 
de bloeddruk meet, of het op geprotocoliseerde wijze door de patiënt zelf een week lang 
meten van de bloeddruk thuis, geven een betrouwbaarder beeld van de ware bloeddruk van 
de patiënt dan een gewone praktijkmeting. Echter, beide meetmethoden kennen een aantal 
beperkingen en daarom hebben we een nieuwe meetmethode gevalideerd voor gebruik in de 
huisartspraktijk.
Tenslotte hebben we onderzocht of het mogelijk is om behandeling op maat te starten bij 
patiënten met een terecht gestelde diagnose hypertensie. Voorgaand onderzoek op dit terrein 
resulteerde in tegenstrijdige bevindingen. Sommige studies suggereren dat  leeftijd, geslacht en 
plasma renine de reactie op verschillende soorten antihypertensiva  kunnen voorspellen, maar 
weer andere studies laten het tegendeel zien. Omdat de meeste van de studies behoorlijke 
methodologische beperkingen hadden en slechts beperkt of niet vertaalbaar bleken naar de 
populatie van mensen met hoge bloeddruk die bij de huisarts komen, hebben we zelf een 
studie naar mogelijke voorspellers verricht. 
Dit proefschrift heeft dan ook de volgende doelstellingen:
1. Bestuderen van de invloed van richtlijnen op het proces en de uitkomsten van 
hypertensiebeleid in de huisartspraktijk
2. Valideren van een 30 minuten, seriële, automatische praktijkbloeddrukmeting 
(30-min APBDM), gemeten in de huisartspraktijk met een 24-uurs bloeddrukmeter
3. Identificeren van patiëntkenmerken die de bloeddruk respons op twee verschillende 
soorten bloeddrukverlagende medicijnen, elk met een eigen pathofysiologisch 
werkingsmechanisme, kunnen voorspellen  
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In Hoofdstuk 2 geven we de resultaten weer van een beschrijvende studie naar de impact van 
de eerste Nederlandse huisartsenrichtlijn over hypertensie en de twee daaropvolgende revisies 
op het proces en de uitkomst van hypertensiebeleid in de huisartspraktijk. We definieerden 
3 cohorten van nieuw gediagnosticeerde patiënten steeds in de periode van 1 jaar na het 
verschijnen van de richtlijn tot aan de introductie van een nieuwe revisie. De gemiddelde leeftijd 
van patiënten in deze cohorten steeg van 55 jaar in het eerste cohort (1992-1996) tot 60 jaar in 
het derde cohort (2004-2006). De gemiddelde bloeddruk waarop met medicatie gestart werd 
verschilde niet significant tussen de drie cohorten (175-179 / 99-106 mmHg). Ook de procentuele 
bloeddrukdaling na 2 jaar behandelen verschilde weinig tussen de cohorten (variërend van 
13,3 tot 15,7% systolisch). De gemiddelde bloeddruk na 2 jaar was 148 – 151 / 85-89 mmHg. 
Het percentage patiënten met drie of meer antihypertensiva bleef vrijwel gelijk (22-23%) in de 3 
cohorten. Passend bij het veranderd advies in de gereviseerde richtlijnen nam het gebruik van 
diuretica als 1e keus medicatie significant toe. Wij concludeerden dat huisartsen en patiënten 
in staat zijn om klinisch relevante en aanhoudende bloeddrukverlaging te bereiken. Echter de 
twee richtlijn revisies lijken de mate van bloeddrukverlaging niet te verbeteren ondanks beter 
geformuleerde en strengere behandeldoelen.
Hoofdstuk 3 rapporteert over onderzoek naar de overeenkomst tussen zittend 30-min 
APBDM in vergelijking met een gestandaardiseerde praktijkbloeddrukmeting en naar de 
reproduceerbaarheid van 30-min APBDM. De gemeten 30-min praktijkbloeddruk bleek 
gemiddeld 8/3 mmHg lager dan bij een gestandardiseerde praktijkbloeddrukmeting. Het 
gemiddelde verschil en de standaard deviatie van het verschil (SDD) tussen twee opeenvolgende 
30-min APBDM’s (3/1 mmHg, 95% CI 1 tot 5/0 tot 2 mmHg; SDD 10/5mmHg) was kleiner 
dan tussen twee opeenvolgende gestandaardiseerde praktijkmetingen (6/2 mmHg, 95% CI 
4 tot 8/1 tot 4 mmHg; SDD 11/6 mmHg). We concludeerden hieruit dat 30-min APBDM beter 
de ware bloeddruk status van een patiënt weergeeft en beter reproduceerbaar is dan een 
gestandaardiseerde praktijkmeting.
Vervolgens geven we in Hoofdstuk 4 de resultaten weer van de vergelijking tussen zittend 
30-min APBDM en de gemiddelde dagwaarde van een 24-uurs bloeddrukmeting. Het 
gemiddelde verschil tussen beide methoden was respectievelijk 0 en 2 mmHg voor de 
systolische en diastolische bloeddruk (met “limits of agreement” tussen -19 en 19 mmHg 
systolisch en -10 en 13 mmHg diastolisch). Patiënten werden zowel door een zittend 30-min 
APBDM als de dagwaarde van de 24-uursmeting vergelijkbaar geclassificeerd in 4 soorten 
bloeddrukcategorieën (normotensief, witte jassen hypertensie, gemaskeerde hypertensie 
en structurele hypertensie). Wij concludeerden uit dit onderzoek dat 30-min APBDM goed 
overeenkomt met de dagwaarde van een 24-uurs meting en dat het de potentie heeft om witte 
jassen hypertensie en gemaskeerde hypertensie op te sporen.    
Hoofdstuk 5 beschrijft tenslotte een vergelijkbaar onderzoek als in hoofdstuk 4 maar nu met 
de 30-min APBDM liggend uitgevoerd. De systolische bloeddruk verschilde -1 (-4 tot 2), 17 (14 
tot 20) en 2 (-1 tot 4) mmHg tussen liggend 30-min APBDM en respectievelijk de dagwaarde, 
de nachtwaarde en het 24-uurs gemiddelde van een 24-uurs bloeddrukmeting (95% BI). 
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De diastolische waarden vertoonden een vergelijkbaar beeld. Patiënten werden zowel door 
liggend 30-min APBDM als de dagwaarde van de 24-uursmeting vergelijkbaar geclassificeerd 
in 4 soorten bloeddrukcategorieën (normotensief, witte jassen hypertensie, gemaskeerde 
hypertensie en structurele hypertensie). Onze conclusie was dat vergelijkbaar met zittend ook 
liggend 30-min APBDM goed overeenkomt met de dagwaarde van de 24-uursmeting, maar dat 
zittend meten onze voorkeur heeft. 
In Hoofdstuk 6 rapporteren we over de resultaten van de NAMI-studie, een cross-over 
onderzoek met als doel om patiëntkenmerken te achterhalen die de respons op een diureticum 
(hydrochloortiazide) of een angiotensine receptor antagonist (valsartan) zouden kunnen 
voorspellen. We bestudeerden leeftijd, geslacht, menopauze, plasma renine concentratie, NT-
pro BrainNatriureticPeptide, kalium, nierfunctie, urine albumine, body mass index (BMI) en 
middelomtrek als mogelijke voorspellers. De bloeddruk respons bepaald met de dagwaarde 
van de 24-uurs meting was de primaire uitkomstmaat. De intra-individuele systolische bloeddruk 
respons varieerde tussen een daling van 39 mmHg en een stijging van 18 mmHg. BMI bleek 
in bescheiden maar significante mate de respons op valsartan te voorspellen (ß -0,63; p = 
0,04), de overige variabelen bleken niet voorspellend. In onze studie vonden we onvoldoende 
aanwijzingen voor het gebruik van patiëntkenmerken bij het optimaliseren van de behandeling 
van ongecompliceerde essentiële hypertensie. Deze resultaten zijn niet in overeenstemming 
met de theoretische onderbouwing voor het behandelschema van de Britse NICE richtlijn over 
hypertensie waarbij leeftijd wordt gebruikt als voorspeller van de behandeling.
Hoofdstuk 7 staat in het teken van een kritische beschouwing van de beschreven resultaten 
in dit proefschrift en beschrijft tevens de klinische implicaties en mogelijkheden voor 
vervolgonderzoek. Met betrekking tot 30-min APBDM concluderen we dat deze meetmethode 
valide lijkt om de ware bloeddrukstatus van de patiënt in de huisartspraktijk te kunnen bepalen. 
Voor de implementatie in de dagelijkse huisartspraktijk is een haalbaarheidsstudie wenselijk 
waarbij zowel het perspectief van zorgverleners en patiënten over gebruiksgemak en toepassing 
vergeleken wordt met thuismetingen en 24-uursmetingen. Daarnaast zal een trial met als doel 
de kosteneffectiviteit vast te stellen van het gebruik van 30-min APBDM ten opzichte van nu 
gebruikelijke zorg in het diagnostisch proces van hoge bloeddruk wenselijk zijn. De resultaten 
van de NAMI studie suggereren dat op de patiënt toegesneden starten met antihypertensieve 
therapie bij ongecompliceerde hypertensie niet mogelijk is met de door ons bestudeerde set 
van mogelijke voorspellers van het effect van behandeling. We hebben een vijftal voorwaarden 
geformuleerd waaraan een variabele moet voldoen om als succesvol voorspeller beschouwd 
te kunnen worden. Aan de hand van deze voorwaarden proberen we de resultaten van de 
NAMI studie te duiden en een verklaring te geven voor de huidige tegenstrijdige resultaten 
op het gebied van onderzoek naar voorspellers voor de behandeling van hypertensie. Met 
de huidige stand van kennis concluderen we dat het niet zinvol lijkt om vervolgonderzoek te 
verrichten naar de voorspellende waarde van de door ons bestudeerde variabelen. Voor de 
dagelijkse praktijk pleiten we er daarom voor om bij de eerste keus voor een antihypertensivum 
bij ongecompliceerde hypertensie zonder cardiovasculaire comorbiditeit de context van de 
patiënt, zijn of haar voorkeur en de medicatiekosten mee te wegen. Daarnaast lijkt het zinvol 
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om te bestuderen of het kosteneffectief is om bij een patiënt middels “trial and error” het best 
werkende eerste keus middel te vinden dan wel om direct te starten met combinatietherapie. 
Dit proefschrift wordt afgesloten met een Epiloog waarin we de resultaten van ons onderzoek 
proberen te plaatsen in de context van recente veranderingen in de maatschappij en de medische 
professie. Ons onderzoek probeert bij te dragen aan een reductie van overdiagnostiek en 
overbehandeling van hypertensie. Echter, wij vinden dat veranderingen in medische wetgeving, 
verkeerde marktwerking in de zorg, een overschatting van de voordelen van preventie en het 
huidige maatschappelijke perspectief op maakbaarheid van gezondheid, individualisering 
en omgaan met risico’s druk op artsen uitoefent om juist overmatig te diagnosticeren en 
behandelen. In deze epiloog beschrijven we een aantal manieren om dit te voorkomen.    
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En dan nu een veel gelezen stukje proefschrift. Daarom heb ik tussen de regels door de kern 
van mijn onderzoek subliminaal verpakt. Lees het en je weet het, al is het maar onbewust. 
Onderzoek doe je gelukkig niet alleen. Je hebt er kennis, kunde, wijsheid en steun van veel 
mensen bij nodig. Ik wil allen die mij direct of indirect hebben geholpen bij het slagen van mijn 
promotietraject ontzettend bedanken! Een aantal wil ik expliciet noemen. 
Allereerst wil ik alle deelnemende patiënten bedanken voor hun bijdrage aan ons onderzoek. 
Je moet het maar willen, eerst een half uur stil blijven zitten of liggen zonder iemand om mee 
te kletsen om daarna ook nog eens 24 uur lang door zo’n bloeddrukmeter lastig gevallen te 
worden. Of nog erger: binnen 18 weken 6 keer (!!) zo’n 24uurs meting. 
Beste Chris, wat ben je toch een Brit. En wat kan ik daar van genieten en leren. Dankzij jouw 
tact en netwerk kregen we van ZonMw geld ter compensatie van het nodige aan procedureel 
ongemak, jij wist mijn soms scherpe replieken bij weer een major revision de juiste toon te 
geven zonder aan inhoud te verliezen, je feedback op onderzoeksvoorstellen en manuscripten 
was buitengewoon waardevol. Bovenal gaf je vertrouwen, je kreeg er een loyale medewerker 
voor terug.
En ik maar denken dat internisten droge, vervelende betweters waren. Uit mijn n=3 
ervaringsstudie heb ik geconcludeerd dat dit geheel niet het geval is, ook al blijven het natuurlijk 
wel een beetje vreemde vogels: 
 
Theo, je kennis over bloeddruk is indrukwekkend en met jouw ervaring was ook het historisch 
perspectief nooit ver weg. Ik zal onze dinsdagochtendsessies met Carel gaan missen, er was 
naast serieus werken altijd wat te lachen. Ik vind het geweldig dat je plaatsvervangend rector 
magnificus wilt zijn tijdens de verdediging van mijn proefschrift.
Jacques, jouw rol was bescheiden, maar niet minder waardevol. Over het NAMI artikel hebben 
we het nodige gestoeid, vooral de discussies over de urgentie en interpretatie van het NAMI 
onderzoek staan me bij. Je zegt waar het op staat, ik waardeer dat zeer. En natuurlijk was het 
heerlijk om onderling te prikken in de clichés van huisartsen en internisten.
Beste Jaap, jij bent een generalist met passie voor patiënten en kennis van veel. Op je poli 
zag ik dat je eigenlijk huisarts bent. Echter zoals jij bloeddruk snapt, gaat mij nooit lukken. Je 
beheerst de kunst van het afdwalen als geen ander, en je kon er mijn ongeduld wel eens mee 
tarten. Andersom leverde het afdwalen ook vaak relativiteit, humor of een nieuw idee op. Ik kon 
altijd bij je terecht, dank je wel daarvoor.
Beste Carel, lieve Carel, ik schrijf dit in de wetenschap dat je er waarschijnlijk niet meer bent als 
ik ga promoveren. Je bent een vaderfiguur voor mij geweest en mijn verdriet is groot.
Gelukkig is de weg zelf de bestemming. Onze weg was vol mooie, inspirerende en meestal 
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vrolijke herinneringen. Van ellenlange discussies over CVRM registratie, tot bier drinken op 
WONCA Singapore, van samen racefietsen langs de Ijssel of in de Elzas, tot samen nascholing 
geven of een modern KetenzorgInformatieSysteem ontwikkelen. Je nimmer aflatende 
nieuwsgierigheid en open staan voor anderen en hun ideeën was jouw voeding voor je rol 
als wetenschapper. Meer nog dan wetenschapper was je volgens mij mentor en onderwijzer. 
Jij leert me –en je bent me daarin ver vooruit- om werkelijk te luisteren, om bescheiden te 
kunnen zijn, niet te snel te oordelen, om het naadje van de kous te weten (en soms dus even te 
vertragen i.p.v. te versnellen) en om je te blijven verwonderen. Wat ga ik je missen.
Hans Bor en Reinier Akkermans, het gouden fietsduo van de statistiek. Het is helaas minder 
makkelijk geworden om zomaar even met een vraagje binnen te lopen. Jullie kennis en kunde 
van simpel SPSS trucje tot beste analyse is indrukwekkend.
Dames van het secretariaat, eerst Twanny, Dorothé en Caroline, later ook Tilly en Loes, wat fijn 
dat jullie er zijn. Soms alleen voor een kort kletsje of de heetste roddels, soms om mij uit de 
brand te helpen met “model 8 bonnen” en wat dies meer zij. Twanny, dankzij jouw voorwerk 
werd mijn proefschrift een geheel zodat mijn broer lekker kon layouten.
Collega onderzoekers van de wat vroegere uurtjes Floris, Lieke, Erik, Patrick, Caroline, Lotte, 
Erwin en wat later ook Annemarie, Machteld, Evelien, Hiske, Wouter, Hilde, Nynke, Jaap en 
Sabine, dank jullie wel voor de broodnodige relativering, humor en gezelligheid naast uiteraard 
ernstige en diepwetenschappelijke gesprekken.
Kamergenoten Wil, Evelyn en later Kees, wat een luxe om als junior onderzoeker tussen allemaal 
seniors te mogen zitten die stuk voor stuk onverminderd junior energie met zich meedragen. 
Wij vonden elkaar in de passie voor de huisartsgeneeskunde en de wetenschap en ik kon mij 
laven aan jullie ervaring en wijsheid. 
Lieve collega’s van Wijkgezondheidscentrum Lindenholt wat voel ik me bij jullie op mijn gemak 
en wat hebben we een geweldig team. Toen ik als eerste aios van het centrum begon kreeg ik 
al snel het gevoel dat het goed zat. Een hoog niveau van kwaliteit, multidisciplinair, koploper, 
gecombineerd met een prettige werksfeer met mensen die allemaal gedreven zijn door de 
inhoud van het vak. Marie José, jij hebt hier een belangrijke bijdrage aan geleverd en me 
hiermee (indirect) verleid om collega te worden. Ysbrand als mijn opleider ben je ontzettend 
waardevol geweest voor mijn ontwikkeling als mens en als huisarts, dankzij jouw feedback 
op mijn consulten ben ik begonnen met snappen en toepassen waar huisartsgeneeskunde 
werkelijk om gaat. 
Huisartsen, doktersassistenten en POH-ers van de NMP praktijken en die van Huisartsenpraktijk 
Winssen, Thujapark Beuningen en de Kroonsteen in Malden ontzettend bedankt voor jullie 
bijdrage aan ons onderzoek. Wat is het goed dat jullie het belang van onderzoek inzien en daar 
een steentje aan bijdragen!
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Graag wil ik ook de Heeren van het Haantje bedanken. Dennis jij bent het geweten van de 
Heeren en houdt de voeten stevig op de grond, zeker nu het pogo tijdperk ver achter ons ligt. 
Remco je grondige en soms rigoureuze aanpak van de dingen waar je voor gaat zijn naast bron 
van hilariteit ook ontzettend waardevol. Beiden zijn jullie vrienden vanaf het eerste studiejaar, 
wat is het toch fijn om te weten dat ik jullie ’s nachts voor alles zou kunnen bellen. 
Gurb, wij gaan nog iets langer terug, je twinkeloogjes en je energie zijn onveranderd, feitelijk 
ben je een boefje met een hart van goud. Met jou is het heerlijk sparren. Op zich is het 
best overdreven om helemaal uit Australië te komen om mij een uurtje te zien stoeien met 
hooggeleerde opponenten, maar ik vind het briljant dat je mijn paranimf wilt zijn. 
Joris het gaat me een keer lukken (het hangt af wat Esther in petto voor me heeft), Ron wanneer 
begin jij? Gabe, succes met verbouwen, aan de architect kan het niet liggen en Ivar, wat heb  jij 
toch altijd een heerlijk aanstekelijke lichtheid om je heen hangen. Heeren, wie prikt de volgende 
datum en wanneer beginnen we nu echt aan het TermiTeam ™?
Beste Martijn, jouw passie voor het leven en voor de natuur is zeer aanstekelijk. Ik voel een 
groot verwantschap met je in onze zoektocht naar worden wie we zijn. Met niemand anders 
kan ik zo in de natuur zijn als met jou. Zullen we de volgende keer wel weer gewoon wat eten 
meenemen?  
Tim, donders wat hebben wij alweer veel avonturen gedeeld: van vrouwen interviewen in 
Florence en rauwe kip eten in Japan tot het organiseren van het NHG congres 2012 over de 
toekomst van ons vak. Onze vriendschap is voor mij een erg waardevolle bonus die ik dankzij 
de wetenschap ontvangen heb. Met jou als paranimf slaap ik nog beter. 
Lieve Jan en Mieke, naast Esther kreeg ik er een onverwacht cadeau bij. Wat zijn jullie lieve, 
zorgzame mensen en wat geniet ik van jullie kennis van de natuur. Elke maandag komen jullie 
helemaal uit Galder om op Ella te passen, hoe ontzettend fijn is dat! Mieke ik vind wel dat je 
mijn overhemden nog beter kunt strijken en Jan ik ben ernstig teleurgesteld dat het trapgat nog 
niet af is!
Sander toen we nog bij moeders woonden hebben we elkaar veel de hersens ingeslagen….. 
en dat schept een band. Met wie anders kan ik de BeetwortelsapShow nog eens ten uitvoering 
brengen of een Wookie imiteren in Torres del Paine? Mijn irritaties zijn door de jaren heen 
vervangen door bewondering voor jouw slimheid, handigheid, nauwkeurigheid en humor. Je 
jeuk voor onrechtvaardigheid is zeer groot, net als je loyaliteit en inzet voor je naasten. Ik ben 
ontzettend blij en trots dat ik één van hen ben. Dank je wel voor al je werk om de inhoud van dit 
proefschrift een schitterende vorm te geven. Nina een betere schoonzus kan ik me niet wensen, 
en je hebt er ook nog voor gezorgd dat ik Ome Mark kan zijn voor Kaan en Sten, de liefste en 
leukste neefjes van heel de wereld!
Lieve Mamma, jij bent de bron van al het kwaad. Zonder jou zou ik nu niet een partij zenuwachtig 
zijn voor de verdediging van mijn proefschrift. Gelukkig kan ik er dankzij jou ook mee dealen. 
Jij hebt  2 puberzonen alleen opgevoed en hebt als een gek gewerkt en gestudeerd om ons 
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te kunnen geven wat we nodig hadden. Het was een wijze les om bij de beste en duurste 
banketbakker gebakjes te halen als je rood stond en zo heb je me nog wel meer gereedschap 
meegegeven om zelfstandig aan mijn eigen leven te kunnen klussen. Ontzettend bedankt voor 
dit kostbare gereedschap en je onverminderde steun! Pa, jij snapt van dit alles niet veel, helaas 
kan je daar niets aan doen.
Wim, bij stiefvaders denken mensen al snel aan een ongeschoren man die met een fles bier in 
de ene hand en een stok in de andere je dagelijks het kolenhok in slaat. Gelukkig ben jij een 
variant daarop, wel met een snor, maar bovenal een goeierd die altijd voor ons klaarstaat.
Het lekkerst voor het laatst! Lieve Esther, wat een koekenbakker ben ik eigenlijk geweest om je 
niet gelijk als geschenk uit de hemel te omarmen en er een paar NHG congressen over te doen 
voordat ik mijn hart durfde te laten spreken. Jij accepteert mij zoals ik ben en gek genoeg (of 
mede daardoor) kan ik dat ook bij jou. Je onvoorwaardelijke liefde en steun voelt als een warm 
bad en heeft me geholpen om ondanks overmatig multitasken niet kopje onder te gaan.  Met 
onze dochter Ella hebben we ons verbond nog hechter gemaakt. 
Ella wat ben je toch een schatje, en wat heerlijk dat je aan “uitslapen” doet! Hoe kan ik je ooit 
leren wat grenzen en spelregels zijn met zo’n ondeugend en verleidelijk lachje?
Es, ik weet dat je met gezonde scepsis naar mijn voornemen luistert om de aankomende jaren 
een paar ballen minder in de lucht te houden zodat ik ook jou meer kan steunen bij je avonturen 
met je praktijk en zeker ook om samen meer gezinstijd te hebben. Toch ben ik dat vast van plan 
en bij deze staat het zwart op wit!
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